



UNIVERSIDADE ESTADUAL DE CAMPINAS - UNICAMP
FACULDADE DE ODONTOLOGIA DE PIRACICABA - FOP



Regiane Yatsuda
Cirurgiã Dentista

“Efeito antimicrobiano *in vitro* da *Mikania laevigata* e
Mikania glomerata sobre estreptococos
do grupo mutans”.

Dissertação apresentada à Faculdade
de Odontologia de Piracicaba da
Universidade Estadual de Campinas,
no Programa de Pós-Graduação em
Odontologia, para obtenção do título
de Mestre em Odontologia, Área de
Farmacologia, Anestesiologia e
Terapêutica.

Piracicaba, SP
2004

Regiane Yatsuda
Cirurgiã Dentista

“Efeito antimicrobiano *in vitro* da *Mikania laevigata* e
da *Mikania glomerata* sobre estreptococos
do grupo mutans”.

Dissertação apresentada à Faculdade de Odontologia de Piracicaba da Universidade Estadual de Campinas, no Programa de Pós-Graduação em Odontologia, para obtenção do título de MESTRE em Odontologia, Área de Farmacologia, Anestesiologia e Terapêutica.

Orientador: Prof. Dr. Pedro Luiz Rosalen
Co-orientador: Prof. Dr. Hyun Koo

Banca Examinadora:
Prof. Dra. Vera L.G. Rehder.
Prof. Dra. Severino Matias de Alencar.
Prof. Dr. Pedro Luiz Rosalen.

Piracicaba, SP
2004

Ficha Catalográfica

Y28e Yatsuda, Regiane.
Efeito antimicrobiano *in vitro* da *Mikania laevigata* e da
Mikania glomerata sobre estreptococos do grupo mutans. /
Regiane Yatsuda. -- Piracicaba, SP : [s.n.], 2004.
x, 55f. : il.

Orientadores: Prof. Dr. Pedro Luiz Rosalen, Prof. Dr.
Hyun Koo.
Dissertação (Mestrado) – Universidade Estadual de Campinas,
Faculdade de Odontologia de Piracicaba.

1. Produtos naturais. 2. Microorganismos. 3.
Plantas medicinais. I. Rosalen, Pedro Luiz. II. Koo,
Hyun. III. Universidade Estadual de Campinas.
Faculdade de Odontologia de Piracicaba. IV. Título.

Ficha catalográfica elaborada pela Bibliotecária Marilene Girello CRB/8-6159, da
Biblioteca da Faculdade de Odontologia de Piracicaba - UNICAMP.

Dedico este trabalho

À *Deus*, pela minha família, amigos e vida

Ao meu pai *Riogi*, por ser uma pessoa compreensiva, sábia, exemplo de dedicação como pai e professor, que me influenciou e incentivou a ser pesquisadora.

A minha mãe *Regina*, por ser uma super mãe, por todo amor, paciência, sacrifícios, oportunidades e pela compreensão desses seis anos da minha ausência na nossa família.

Ao meu irmão *Regis*, por toda amizade, carinho, ajuda, exemplo e apoio na escolha da minha carreira.

À *Fabiana*, sempre amiga e confidente.

Ao *Fernando*, por estar do meu lado e me ajudar em alguns momentos do mestrado, sacrificando parte de suas férias e tendo que agüentar mais um pouco de Piracicaba.

Meus sinceros agradecimentos,

A Universidade Estadual de Campinas, por meio do Reitor Carlos Henrique de Brito Cruz.

A Faculdade de Odontologia de Piracicaba (FOP-UNICAMP), por meio do diretor Thales Rocha de Mattos Filho.

Ao Departamento de Ciências Fisiológicas da FOP, por meio do chefe de departamento Pedro Luiz Rosalen.

Ao Prof. Dr. Lourenço C. Sobrinho, coordenador dos cursos de Pós-Graduação da FOP/UNICAMP e à Prof. Dra. Maria Cristina Volpato, coordenadora do Programa de Pós-Graduação em Odontologia.

Aos professores e amigos da Área de Farmacologia, Anestesiologia, e Terapêutica, Profa. Maria Cristina, Prof. Francisco Groppo, Prof. José Ranali, Prof. Eduardo, e Prof. Thales, Prof. Pedro e a todos os docentes do Programa de Pós-Graduação em Odontologia de Piracicaba.

Ao CPQBA (Centro Pluridisciplinar de Pesquisas Químicas, Biológicas e Agrícolas), pela colaboração ao projeto no fornecimento de extratos e compostos isolados da planta, além das suas análises químicas.

À FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo), pelas bolsas de estudos concedidas (processos # 99/12007-0 e 01/11809-8).

AGRADECIMENTOS

Ao meu orientador *Prof. Dr. Pedro Luiz Rosalen*, minha gratidão por todos esses anos de oportunidades, orientação e amizade, exemplo de professor e seriedade.

Ao meu co-orientador *Prof. Dr. Hyun Koo (Michel)*, exemplo de pesquisador, orientador e amigo, mesmo longe sempre presente, de quem sinto muito orgulho.

A *Profa. Vera L. G. Rehder*, pela orientação direta, amizade, sempre disposta a colaborar com o projeto, fornecimento de quilos de extrato, participação e colaboração fundamental neste experimento.

Ao *Prof. Dr. Robert Marquis* e *Prof. Dr. William H. Bowen*, da Universidade de Rochester, que gentilmente cederam material e microrganismos usados neste projeto.

Ao *Prof. Dr. Jaime Aparecido Cury*, da Área de Cariologia da FOP-UNICAMP, pesquisador extraordinário, pela ajuda e orientação dada na realização desse projeto.

Ao *Prof. Dr. Reginaldo Gonçalves*, do Laboratório de Microbiologia e Imunologia da FOP-UNICAMP, co-orientador da iniciação científica, pela orientação e pelos microrganismos gentilmente cedidos.

Aos *Professores Reginaldo Gonçalves, Francisco Carlos Groppo, Cinthya P.M. Tabchoury* e *Jaime A. Cury*, membros da banca de qualificação, pelas sugestões para realização e finalização deste projeto.

Ao amigo *Leandro* do CPQBA, por toda dedicação e amor a *Mikania*, pelo fantástico trabalho de fornecimento dos extratos e compostos isolados da planta, sempre enormes quantidades em pouco tempo, com excelente qualidade.

AGRADECIMENTOS

Ao *Ramiro*, que me trouxe para a Farmaco, sempre companheiro e grande amigo, a quem divido todo o mérito desse projeto.

Ao amigo, *Marcelo Henrique Napimoga*, “Hermetos”, por sua atuação direta no isolamento de microrganismos tanto no projeto de iniciação científica quanto no do mestrado, além de toda amizade e ajuda com microbiologia.

À *Flavinha*, além de uma grande amiga, uma excelente “orientada”, responsável, sempre bem humorada e atenciosa, por todas horas cedidas e inestimável ajuda para realização desse projeto.

À *Mairão*, pela excelente paciência, companhia e toda colaboração neste projeto.

À *Simone* por toda sua energia, paciência ensinando os primeiros passos no laboratório e ajudando muito nas correções dos artigos.

À *Iriana, Lidiany, Mitsue, Adriana e Gi Pecharki* por toda colaboração na metodologia desse projeto.

Às amigas *Ana Paula e Flávia Flório* pela grande ajuda na análise estatística dos resultados.

À *Ju Cama* grande amiga de todas as horas, com quem aprendo muito todos os dias, exemplo de pesquisadora e professora.

Aos amigos da Farmacologia, Cariologia e Fisiologia, *Giovana, Ana Paula, Rogério, Gilson, Roberta, Sinvaldo, Karla, Marcos, Filipe, Mitsue, Fório, Gi Pecharki, Carol Aires*,

AGRADECIMENTOS

Juliana Clemente, Maria Cláudia e Luciano por compartilharem dúvidas, angústias, conhecimentos e claro, por tornarem o mestrado mais leve, divertido e suportável.

Ao *Jorge e Juliana*, pela colaboração, churrascos, correções dos artigos e amizade.

À *Crica, Bruno, Goiano, Foquinha, Carol Aires, Caio e Flávia Gamba* amigos da graduação e colegas de pós-graduação, por todo companherismo, ajuda nos momentos difíceis e pela descontração também. É sempre bom tê-los por perto.

À *Van, Carol Japeta, Márcio, Paulino, Bianca e Zé*, eternos amigos que de inúmeras formas me ajudaram na graduação e iniciação científica.

À *Jéssica, Fernanda, Ju PA, Fer Singhoretti e Adriano*, amigos tão especiais que me incentivam e me apoiam sempre. Ao Canil, minha segunda casa em Pira.

À *Eliane*, excelente técnica de laboratório, amiga e confidente, sempre incentivando, ajudando e dando sábios conselhos.

À *Elisinha*, sempre calma e prestativa, por sempre me ajudar e lembrar-me dos prazos.

Ao *Chico Groppo*, por todos os conselhos e dicas, tanto no projeto quanto fora da Farmaco.

Ao *José Carlos* funcionário da Farmacologia, pela ajuda no laboratório.

À *Aline, Maitê, Carolzinha, Adriana e Myrella*, estagiárias da Farmaco, por toda ajuda na realização desse projeto.

AGRADECIMENTOS

À minha tia *Hissayo* e *Delfina*, por toda iluminação, carinho e força, mesmo longe de mim.

Aos amigos e pessoas que embora não citadas colaboraram e incentivaram para que este trabalho fosse realizado.

SUMÁRIO

RESUMO	01
ABSTRACT	03
1. INTRODUÇÃO	05
2. CAPÍTULOS	11
2.1. Título 1	12
2.2. Título 2	31
3. CONCLUSÕES	50
4. REFERÊNCIAS BIBLIOGRÁFICAS	51
5. ANEXOS	55
5.1. Anexo 01	55
<i>- E-mail de recebimento do artigo pela revista Journal of Ethnopharmacology</i>	

RESUMO

O objetivo geral do trabalho foi avaliar o efeito antimicrobiano da *Mikania laevigata* e *Mikania glomerata* (guaco) sobre os estreptococos do grupo mutans. Portanto, foram realizados 2 estudos, sendo o objetivo do estudo 1 analisar a composição química e o efeito antimicrobiano dos extratos e frações da *Mikania laevigata* e da *Mikania glomerata* sobre o crescimento bacteriano e a aderência celular dos estreptococos do grupo mutans. O objetivo do estudo 2 foi avaliar o efeito dos compostos isolados da *Mikania* sobre a viabilidade das células dos estreptococos do grupo mutans em biofilme (BF) e durante sua formação. Para o estudo 1 foram feitos extratos hidroetanólicos, frações hexânicas e de acetato de etila, sendo analisados quanto a sua composição química por cromatografia gasosa acoplada a espectrometria de massa (CG/MS). Os extratos e frações foram avaliados microbiologicamente por meio das determinações da concentração inibitória mínima (CIM), concentração bactericida mínima (CBM) e da inibição da aderência celular à superfície de vidro dos microrganismos do grupo mutans, utilizando os métodos descritos por Koo *et al.*, 1999. As frações hexânicas da *M. laevigata* e *M. glomerata* apresentou os melhores resultados antimicrobianos dentre as outras frações testadas (CIM entre 12,5 a 100 µg/mL e CBM entre 12,5 µg/mL a 400 µg/mL) e inibição da aderência celular entre 3,125 e 12,5 µg/mL). Para o estudo 2, os compostos ativos da fração hexânica da *Mikania* foram isolados e identificados por métodos espectroscópicos, sendo isolados 16 compostos diferentes como o ácido cupressênico, ácido diterpênico, ácido caurenóico, cumarina e ácido glandifórico, dentre outros. Entretanto, somente os ácidos cupressênico, diterpênico e caurenóico apresentaram atividade antimicrobiana nos testes de CIM e CBM, sendo esses 3 ácidos os compostos testados (concentrações 1, 10 e 100 vezes a CIM) sobre a viabilidade (*time-kill*) e inibição da formação do biofilme (IFB) de *Streptococcus mutans* UA 159 e *S. sobrinus* 6715. Os BFs foram formados sobre lâminas de vidro obtendo-se uma concentração final de 10⁸ ufc/BF. Os resultados de *time-kill* e IFB foram expressos em log N/N₀, sendo N₀ as ufc do controle negativo e N as ufc formadas após os tratamentos. Para o teste IFB foram realizadas as determinações de

polissacarídeos insolúveis e proteínas totais desse biofilmes. Os testes foram realizados em 6 duplicatas. Os resultados foram submetidos à análise estatística ANOVA e Tukey-Kramer HSD ($p < 0,05$). Os ácidos diterpênico e cupressênico apresentaram atividade bactericida no teste de viabilidade bacteriana nas concentrações de 100 vezes a CIM para *S. mutans*, e o ácido caurenóico reduziu o número de células viáveis, entretanto não sendo bactericida. Nenhum dos compostos testados apresentou atividade bactericida para *S. sobrinus* após 4 h de tratamento. No teste IFB, nenhum dos extratos testados apresentou atividade bactericida para *S. mutans* e somente a fração hexânica 1250 $\mu\text{g/mL}$ foi bactericida para *S. sobrinus*. O ácido diterpênico e o ácido cupressênico foram os únicos compostos efetivos reduzindo a produção de polissacarídeos insolúveis e proteínas totais nos biofilmes, sendo que o ácido diterpênico apresentou os melhores efeitos antimicrobianos em modelo de biofilme. Desta forma, concluímos que os ácidos cupressênico e diterpênico da *Mikania* possuem potencial antimicrobiano, atuando sobre o biofilme dental em baixa concentração, demonstrando serem promissores agentes anti-cárie e anti-placa.

ABSTRACT

The overall aim of this study was to evaluate the antimicrobial effect of *Mikania laevigata* and *Mikania glomerata* (guaco) on mutans streptococci. Therefore, two studies were carried out. The aim of study 1 was to analyze the chemical composition and the antimicrobial effect of crude extract and fractions of *M. laevigata* and *M. glomerata* on bacterial growth and cell adherence of mutans streptococci. The aim of study 2 was to evaluate the effect of the isolated compounds of *Mikania* on the population of viable cells of mutans streptococci in biofilm or during its accumulation. In study 1, the composition of crude hydroalcoholic extracts, hexane and ethyl acetate fractions of both *Mikania* were chemically analyzed by Gas Chromatography with mass spectroscopy analysis coupled with a Mass Detector (GC-MS). The antimicrobial activity of crude extracts and fractions were assessed by determination of minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and inhibition of cell adherence (Adh) to glass surface of mutans streptococci, as described by Koo *et al.*, 1999. The hexane fractions from both plants was the most effective in inhibiting the growth of all the bacterial strains tested (MIC 12.5 to 100 $\mu\text{g/mL}$ and MBC 12.5 $\mu\text{g/mL}$ to 400 $\mu\text{g/mL}$) and adherence cells (3.125 e 12.5 $\mu\text{g/mL}$). In study 2, the active compounds from hexane fraction of *Mikania* were isolated and identified by spectroscopy methods (NMR ^1H and ^{13}C) finding 16 different compounds as cupressenic, diterpenic, kaurenoic, glandifloric acids, coumarin and octadecene, among others. Although, only the cupressenic, diterpenic and kaurenoic acids showed antimicrobial activity for MIC and MBC tests against mutans streptococci, which were tested (concentration 1, 10 e 100 times MIC) on killing assays (*time-kill*) and inhibition of biofilm formation (IBF) of *Streptococcus mutans* UA159 and *S. sobrinus* 6715 biofilms. The biofilms were formed on standard glass microscope slides with TSB/sucrose. The results of time-kill and IBF were expressed in $\log N/N_0$ where N_0 is the number of colony of the negative control and N is the cfu produced after the indicated times of treatment. The biofilms of IBF test were dried and used to determine insoluble polysaccharide by colorimetrically method and total protein concentration in

biofilms based on Lowry method. All of the assays were carried out in six duplicates and statistical analyses were carried out. The data were analysed using Anova and Tukey-Kramer HSD test ($p < 0.05$). In the time-kill test, diterpenic and cupressenic acids at concentrations of 100 times MIC, showed bactericidal effects on *S. mutans* biofilm. However, none of the agents tested were bactericidal for the *S. sobrinus* biofilms, showing that kaurenoic acid was the compound that better reduced the number of viable cells after 4 h of treatment. In the IBF, none of the agents tested appeared to be bactericidal for *S. mutans* biofilms and only hexane fraction 1250 $\mu\text{g/mL}$ was bactericidal to *S. sobrinus*. The cupressenic and diterpenic acids were the compounds that effectively reduced the insoluble polysaccharide and total protein in biofilms, revealing the diterpenic acid showed the major antimicrobial effect among the other compounds tested, reducing the viable cells in biofilm model. In conclusion, the cupressenic and diterpenic acids of *Mikania* have relevant antimicrobial activity against mutans streptococci on biofilms at low concentration and are promising anti-caries and anti-plaque agents.

1. INTRODUÇÃO

A cárie e a doença periodontal são as infecções bacterianas mais comuns nos seres humanos (Loesche, 1986), sendo que a placa dental tem sido extensivamente estudada pela sua relação com estas infecções (Gibbons e van Houte, 1975).

Placa dental é um biofilme bacteriano encontrado naturalmente na superfície dos dentes, apresentando composições bacteriana e bioquímica que podem variar em dependência de fatores intrínsecos e extrínsecos (Marsh, 1992).

O biofilme é benéfico ao hospedeiro na medida em que ajuda a prevenir a colonização de microrganismos exógenos e patógenos. Sua composição é relativamente estável apesar da exposição regular a mudanças no ambiente oral. Entretanto esta estabilidade pode deixar de existir quando ocorrem alterações do meio oral, conduzindo a um desequilíbrio da microbiota bucal residente, favorecendo o estabelecimento de uma população microbiana cariogênica (van Houte, 1994; Loesche, 1986; Marsh, 1992, 1994). Subseqüentemente, bactérias colonizadoras secundárias se aderem aos residentes já aderidos (co-agregação) por interações moleculares específicas. Este processo contribui para a determinação do padrão de sucessão bacteriano, formando um biofilme patogênico, também conhecido como “placa dental, doença” ou biofilme patogênico. (Marcote e Lavoie, 1998).

Um dos fatores de desequilíbrio fundamental para o aparecimento de uma placa dental cariogênica é a dieta rica e freqüente de carboidratos fermentáveis, principalmente a sacarose. Esta dieta promove um aumento da proporção de estreptococos do grupo mutans, uma vez que estes microrganismos apresentam algumas vantagens ecológicas quando da presença deste açúcar no meio bucal, permitindo a sua aderência, colonização e posterior acúmulo na superfície lisa do esmalte dental (Hamada e Slade, 1980; Loesche, 1986). Além disso, a fermentação de carboidratos da dieta pelas bactérias, principalmente sacarose, resulta na produção de ácidos e produtos que inicialmente desmineralizam o esmalte e posteriormente a dentina, sendo que, quando

esse processo não é controlado, ocorre à formação das lesões cariosas (Alam *et al.*, 2000; Bowden, 1990).

Os estreptococos do grupo mutans, além de serem acidúricos e acidogênicos, não só fermentam a sacarose como, a partir desta, sintetizam glucanos através das enzimas glucosiltransferases - GTFs (Gibbons e van Houte, 1975; Hamada e Slade, 1980). Atualmente, três GTFs distintas, secretadas pelo *Streptococcus mutans*, estão bem caracterizadas tanto bioquimicamente como ao nível molecular: 1) GTF B - codificado pelo gene *gtfB*, que sintetiza glucanos insolúveis em água tendo ligações glicosídicas principais α (1 $\rightarrow$ 3); 2) GTF C - codificado pelo gene *gtfC*, que sintetiza uma mistura de glucanos insolúveis e solúveis, este último apresentando ligações glicosídicas principais α (1 $\rightarrow$ 6); e 3) GTF D - codificado pelo gene *gtfD*, que sintetiza basicamente glucanos solúveis (Loesche, 1986; Hanada e Kuramitsu, 1989). A GTF produzida por *S. sanguinis* (GTF Ss) pode também estar envolvida com o desenvolvimento da placa dental. Os glucanos, principalmente os insolúveis em água, têm sido considerados como os principais fatores de aderência e acúmulo de estreptococos cariogênicos sobre a superfície dental (Hamada e Slade, 1980; Rölla *et al.*, 1983; Tanzer *et al.*, 1985; Schilling, 1992). Em acréscimo, tem sido demonstrado que estes glucanos aumentam a porosidade (Dibdin e Shellis, 1988; van Houte, 1994) bem como causam mudanças na composição inorgânica da matriz da placa (Cury *et al.*, 1997), tornando-a ainda mais cariogênica. Assim, estreptococos do grupo mutans e glucanos são considerados fatores críticos no desenvolvimento da placa dental cariogênica.

Deste modo, estratégias têm sido estudadas no sentido de prevenir a cárie dental e a doença periodontal, seja inibindo o crescimento dos estreptococos do grupo mutans na cavidade bucal ou inibindo a aderência destas bactérias à superfície dos dentes através da inibição da atividade das GTFs, principalmente aquelas responsáveis pela síntese de glucanos insolúveis (GTF B e C), impedindo assim a formação da placa dental. Um agente que eficientemente possuísse propriedades antimicrobianas e inibisse as GTFs seria extremamente desejável para a prevenção destas doenças bucais (Koo *et al.*, 2002).

Nas últimas décadas têm sido observado mundialmente um crescente interesse global no aproveitamento da biodiversidade, particularmente no que se refere às plantas medicinais, que têm sido utilizadas em várias áreas da saúde como uma expressiva forma alternativa de tratamento e prevenção (Lewis e Elvin-Lewis, 1977). O comércio de medicamentos fitoterápicos vem crescendo a uma taxa anual média de 15%, sendo que cerca de 30% dos medicamentos comercializados atualmente são originados direta ou indiretamente de produtos naturais, principalmente de plantas (Farnsworth, 1985; Elisabetsky, 1987).

Esse grande consumo atual de medicamentos fitoterápicos pela população decorre basicamente do fato de que representam formas de terapia mais baratas e /ou naturais que aquelas normalmente oferecidas e preconizadas pela indústria farmacêutica e a medicina alopática. Dentro desse contexto, o aumento do uso destas plantas seria de grande utilidade principalmente nos países em desenvolvimento como o Brasil, que ainda possui grande biodiversidade e tem uma posição privilegiada por possuir cerca de 25% da flora mundial (Farnsworth, 1985).

Dentro dessa perspectiva de aumento do mercado de medicamentos, a participação das plantas medicinais é, sem dúvida, muito importante, particularmente no que tange o desenvolvimento de medicamentos fitoterápicos e a identificação de novas moléculas ou protótipos básicos para geração de novos medicamentos sintéticos. É verdade também, que muitos constituintes de plantas e /ou seus derivados semi-sintéticos constituem uma parcela apreciável dos medicamentos de ponta recém introduzidos no mercado.

Assim, a procura pela descoberta de novos produtos naturais com atividade antibacteriana para a prevenção de doenças bucais e talvez com menores efeitos adversos quando comparados aos produtos industrializados seriam muito importantes para obtenção de um meio efetivo de controle da formação de um biofilme patogênico. Porém, para avaliar a efetividade destes produtos naturais, são necessárias análises progressivas começando com estudos laboratoriais *in vitro*, passando por modelos de estudo *in vivo* e culminando com os estudos clínicos longitudinais (Ten Cate e Marsh,

1994).

Diante desse contexto, muitos estudos já estão sendo realizados identificando e isolando os princípios ativos presentes nestes extratos naturais, para que estes novos compostos isolados quimicamente, se efetivos na sua ação antimicrobiana, possam ser sintetizados e utilizados no controle da doença cárie.

Como mencionado anteriormente, o uso de plantas medicinais vem crescendo nos últimos anos e isto é devido principalmente as descobertas de suas propriedades biológicas, e entre estas plantas destacam-se as do gênero *Mikania*. Segundo Cruz e Liberalli (1938), a maioria das espécies pertencentes ao gênero *Mikania* possui emprego na terapêutica popular, merecendo destaque especial àquelas conhecidas pelo nome de “guaco” ou “guaco cheiroso”. Oliveira *et al.* (1984) afirmam que o guaco é uma das plantas medicinais mais empregadas no Brasil devido aos seus efeitos farmacológicos: antiespasmódico, analgésico (Ruppelt *et al.*, 1991), antiasmático, antibacteriano (Yatsuda, 2001, 2002, 2003), antifúngico (Davino *et al.*, 1989) antiinflamatório (Ruppelt *et al.*, 1991; Pereira *et al.*, 1994), antiprotozoário, antitussígeno, antialérgico (Fierro *et al.*, 1999), broncodilatador, cicatrizante, expectorante, anti-sifílico, antifebril, antiespasmódico e antiúlcera.

As plantas do gênero *Mikania* foram descritas por Willdenow em 1804, recebendo esta nomenclatura em homenagem ao professor Joseph Gottfried Mikan, de Praga. Para o gênero são citadas cerca de 430 espécies, distribuídas principalmente na América Central e do Sul, sendo 200 espécies no Brasil, distribuídas principalmente nas regiões Sul e Sudeste (King e Robinson, 1987). Apesar de apresentar um grande número de espécies, o gênero *Mikania* foi pouco estudado no Brasil. Diversas espécies do gênero *Mikania* são citadas e empregadas em outros países da América do Sul e Central, todas pertencentes à família Compositae (Ritter *et al.*, 1992).

A espécie *Mikania glomerata* Spreng é a única espécie oficializada na 1ª edição da Farmacopéia Brasileira (da Silva, 1929) e foi identificada por Sprengel em 1826, sendo também conhecida por: *Cacalia trilobata* Vell., *M. amara*, *M. aspera*, *M. attenuata*, *M. scansoria* DC., *M. hederæfolia* DC., *Willoughbya glomerata* (Spreng), *Willoughbya moronoa* (Ktze),

sendo popularmente conhecida pelos nomes de guaco, guaco liso, guaco de cheiro, erva de serpente e cipó caatinga (Lucas, 1942; Oliveira *et al.*, 1984). É um subarbusto trepador de ramos lenhosos e de folhas verde-brilhante que, ao serem esfregadas, exalam um forte aroma de baunilha (Vanila) (Oliveira *et al.*, 1984). O seu habitat é nas margens e interiores de matas, adaptando-se muito bem ao cultivo doméstico. Na época da floração torna-se uma planta muito procurada pelas abelhas melíferas. (Ritter *et al.*, 1992; Lucas, 1942; Corrêa, 1952).

A família Compositae, à qual pertence esta espécie, é caracterizada quimicamente pela riqueza em produtos do metabolismo secundário (Gibbs, 1974). A *M. glomerata* apresenta vasta variedade de compostos, tais como ácidos orgânicos, açúcares, materiais corantes, resinas, taninos, cumarina, saponinas, o estigmasterol e um éster alifático, cinamoilgrandiflórico, ácido caurenóico (Oliveira *et al.*, 1984; Santos *et al.*, 1992). No período da floração, agosto a dezembro, ocorre um aumento da concentração dos princípios ativos na planta, decrescendo a produção desses compostos após a floração (Ritter *et al.*, 1992). Dentre os compostos isolados e identificados alguns apresentam atividades farmacológicas destacam-se os diterpenos da classe dos cauranos e cumarinas (Egan *et al.*, 1990; Roskopf *et al.*, 1992; Pereira *et al.*, 1994; Ruppelt *et al.*, 1991; Davino *et al.*, 1989).

Apesar das vastas aplicações populares, a literatura traz poucos estudos científicos sobre a ação antimicrobiana do “guaco”, principalmente em relação a bactérias orais. Em estudos de Alves *et al.* (1995), o extrato bruto das folhas de guaco (*Mikania cordifolia*) demonstrou atividade antiprotozoária (*Trichomonas vaginalis* e *Trypanosoma cruzi*), *in vitro*, e ação antibacteriana e anticândida. Trabalhos desenvolvidos por Yatsuda *et al.* (2001 e 2002), demonstraram que o extrato bruto da *M. laevigata* apresenta atividade antimicrobiana e é capaz de inibir *in vitro* a aderência celular de *S. sobrinus*.

Deste modo, devido à carência de informações do potencial antimicrobiano das *M. laevigata* e da *M. glomerata* e de seus compostos químicos sobre os patógenos bucais, o objetivo do presente estudo foi analisar o efeito antimicrobiano *in vitro* da *Mikania*

laevigata e *Mikania glomerata* e seus compostos sobre os estreptococos do grupo mutans em modelo de células planctônicas e em modelo de biofilme.

2. CAPÍTULOS

Esta tese está de acordo com a Informação CCPG 001/98, UNICAMP, que regulamenta o formato alternativo para dissertação e tese, permitindo a inserção de artigos científicos de autoria ou co-autoria do candidato.

Assim sendo, esta tese é composta de 2 estudos que se encontram em fase de submissão em revistas científicas conforme descrito abaixo:

Estudo 1: “Effects of *Mikania* genus plant on growth and cell adherence of mutans streptococci.”

Estudo 2: “Antimicrobial activity of compounds isolated from *Mikania* sp. on mutans streptococci biofilms”.

O estudo 1 foi submetido a revista Journal of Ethnopharmacology e o estudo 2 será submetido a revista Planta Médica.

O objetivo geral deste trabalho foi analisar *in vitro* o efeito antimicrobiano das plantas *Mikania laevigata* e *Mikania glomerata* sobre os estreptococos do grupo mutans em células planctônicas e em biofilme.

2.1. Estudo 1

Title: Effects of *Mikania* genus plant on growth and cell adherence of mutans streptococci.

Regiane Yatsuda^{a*}, Pedro L. Rosalen^a, Jaime A. Cury^a, Vera L. G. Rehder^c, Leandro V. Melo^c, Ramiro M. Murata^a, Hyun Koo^b.

^a Department of Physiological Sciences, Faculty of Dentistry of Piracicaba, State University of Campinas (UNICAMP), SP, Brazil.

^b Center for Oral Biology and Eastman Department of Dentistry, University of Rochester Medical Center, Rochester, New York, USA

^c Pluridisciplinar Center of Chemical, Biological and Agricultural Researches, CPQBA/ UNICAMP, Brazil.

Running title: *Mikania* and mutans streptococci

Full address of corresponding author, to whom requests for reprints should be addressed:

Pedro Luiz Rosalen
Faculty of Dentistry of Piracicaba, State University of Campinas,
Department of Physiological Sciences
Caixa Postal 52, 13414-900
Piracicaba, SP, Brazil
Tel.: (55) 19-34125313
e-mail: rosalen@fop.unicamp.br or reyatsuda@yahoo.com

SUMMARY

The aim of this study was to evaluate the chemical composition and the antimicrobial activity of the extracts and fractions of *Mikania laevigata* and *Mikania glomerata* on growth and cell adherence of mutans streptococci. Ethanolic extract (EE) and two fractions (hexane-H and ethyl acetate-EA) of *M. laevigata* (Ml) and *M. glomerata* (Mg) were chemically identified by chromatographic methods and tested on mutans streptococci from culture collection and clinical isolates. 22 chemical compounds were identified in both *Mikania*, and the main compounds were coumarin, spathulenol, diterpenic, cupressenic and kaurenoic acids. Antimicrobial activity was assessed by determination of the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and inhibition of cell adherence (Adh) to a glass surface. H fraction from both plant extracts was the most effective in inhibiting the growth of all the bacterial strains tested (MIC 12.5 up to 400 $\mu\text{g mL}^{-1}$, MBC 25 up to 400 $\mu\text{g mL}^{-1}$). In addition, sub-MIC levels of the crude extracts and their H fractions significantly inhibited the adherence of all microorganisms to a glass surface. Overall, MIC and MBC values for the clinical isolates microorganisms were higher than those obtained from culture collection strains. The data indicate that non polar hexane fraction of both *Mikania* species harbors most of the active compounds, showing remarkable inhibitory activities against mutans streptococci. *Mikania* genus plant is a promising source for novel antimicrobial agents against oral pathogens.

KEYWORDS: *Mikania*, mutans streptococci, antibacterial, adherence, biofilm.

RUNNING TITLE: Antimicrobial effect of *Mikania* against mutans streptococci.

INTRODUCTION

Natural products have been used for thousand of years in folk medicine, and are promising sources for discovery of novel potentially therapeutic agents (Cragg, 1997; Harvey, 2000). Nowadays they have been used and also investigated more thoroughly as promising agents to prevent oral diseases, especially plaque-related diseases such as dental caries (Wu-Yuan *et al.*, 1988; Cai and Wu, 1996; Park *et al.*, 1998; Koo *et al.*, 1999; Koo *et al.*, 2002).

Among various medicinal plants used in folk-medicine in Brazil, *Mikania* genus plant, a sub-scrub creeper of woody branches, known popularly as “guaco” (Celeghini *et al.*, 2001), stands out because of its multiple pharmacological properties, especially anti-inflammatory and antimicrobial activities (Ruppelt *et al.*, 1991; Correa, 1942, Pereira *et al.*, 1994; Yatsuda *et al.*, 2001, 2002; de Moura, 2002; Davino, 1989; Paul *et al.*, 2000; Fierro, 1999).

The genus *Mikania* has about 430 species distributed in the tropical areas of Africa, Asia and America (King and Robinson, 1987). In Brazil, the genus is widely distributed, with about 200 described species (Barroso, 1986). The most studied species are *Mikania laevigata* and *Mikania glomerata*. However, only 10% of *Mikania* has been chemically studied (Fabbri *et al.*, 1997). Fifteen compounds have been chemically identified and isolated, and the major compounds are coumarin (Vilegas *et al.*, 1997), coumaric acid, sesquiterpenes and diterpenes (Limberger *et al.*, 2001).

Diterpenic compounds and coumaric acid isolated from the *Mikania* fractions exhibited antimicrobial activity against *Micrococcus luteus*, *Staphylococcus aureus* and *Bacillus subtilis* (Beghetti *et al.*, in press). Kaurenoic acid derivatives substituted on carbon -15 showed antimicrobial and antifungal activities against some pathogens as described by Davino *et al.* (1989). Our preliminary studies have shown that crude extracts of *Mikania laevigata* and *M. glomerata* display promising antimicrobial activity against mutans streptococci, showing inhibitory concentrations as low as 25 µg mL⁻¹ (Yatsuda *et al.*, 2001, 2002).

Mutans streptococci are the main group of microorganism associated with the pathogenesis of dental caries (Loesche, 1986). These bacteria are commonly found in

human dental plaque (Whiley and Beighton, 1998). In addition, mutans streptococci have the ability to adhere and accumulate on the tooth surface by synthesizing extracellular polysaccharides from sucrose (Tanzer *et al.*, 1985; Schilling and Bowen, 1992). This sucrose-dependent adherence and the consequent accumulation of cariogenic streptococci are critical for the development of pathogenic dental plaque related to caries (Hamada and Slade, 1980; Loesche, 1986). Therefore, one of the strategies to prevent the formation and development of dental caries is to control the growth and adherence of mutans streptococci.

Considering the antimicrobial potential of *M. laevigata* and *M. glomerata* against oral pathogens, the aim of this study was to evaluate the chemical composition and the antimicrobial activity of extracts and fractions of *M. laevigata* and *M. glomerata* on growth and cell adherence of mutans streptococci.

MATERIALS AND METHODS

Plant material and chemical studies

The aerial parts of *Mikania laevigata* Schultz Bip. ex Baker and *Mikania glomerata* Sprengel were collected from experimental field at the Pluridisciplinar Center of Chemical, Biological and Agricultural Researches - CPQBA/UNICAMP, Campinas, SP, Brazil. Voucher specimen of *M. laevigata* and *M. glomerata* are deposited at Herbarium of Biology Institute of Unicamp at Campinas under number UEC - 102.046 and UEC 102047, respectively. The leaves were allowed to dry under air circulation (40 °C) for three days and ground for uses.

Extraction and fractionation

The resulting powder (400 g) was submitted to dynamic maceration with 2 L of ethanol: water at (70:30) solution during 3 hours. The extracts were filtered and this procedure was repeated twice. Then, the extracts were concentrated under reduced pressure and lyophilized resulting in 79.1 g of the *M. laevigata* extract (EE-*MI*) and 58.2 g of the *M. glomerata* extract (EE-*Mg*).

The hexane fractions were prepared using 20 g of the extracts EE-*MI* and EE-*Mg* using 70 mL hexane for each extract. The extractions were repeated three times in dispersor Ultra-Turrax. The fractions were concentrated using a rotative evaporator obtaining the

hexane fractions: H-*Ml* (2.8 g) and H-*Mg* (2.6 g). The residues of the extractions described above were used to make the ethyl acetate fraction. The fractions of ethyl acetate: EA-*Ml* (2.4 g) and EA-*Mg* (0.32 g).

The hydroalcoholic extracts (EE-*Ml* and EE-*Mg*), hexane fractions (H-*Ml* and H-*Mg*) and the ethyl acetate fractions (EA-*Ml* and EA-*Mg*), were analyzed by Thin Layer Chromatography - TLC using hexane: ethyl acetate 80:20 (detection anisaldehyde solution). The extracts were analyzed by Gas Chromatography coupled with a Mass Detector (GC-MS) (Beghetti *et al.*, in press). Before the GC-MS analysis, the extracts were methylated using diazomethane solution. The analyses for GC-MS were obtained in a Hewlett-Packard 5890 Model II automated gas chromatograph mass spectrometer data system with selective mass detector Hewlett-Packard 5971 equipped with a capillary column J&W Scientific DB-5 (25m x 0.2mm x 0.33 m), with injector 250 °C and detector 300 °C. The GC-MS peaks were identified by computer searches in commercial reference libraries. Good spectral matches for some compounds could be found in the Wiley and National Bureau of Standards (NBS) mass spectral library and for comparison with pattern of the isolated compounds previously (kaurenoic acid, cupressenic acid, coumarin, spathulenol).

Antimicrobial assays

Microorganisms²

The microorganisms used in this study were *Streptococcus mutans* Ingbritt 1600, *Streptococcus mutans* OMZ 175 and 3 recent clinical isolates (*Strep. mutans* P20, *Strep. mutans* P6 and *Strep. mutans* D1); *Streptococcus sobrinus* 6715 and 3 recent clinical isolates (*Strep. sobrinus* P7, *Strep. sobrinus* S2 and *Strep. sobrinus* S17); and *Streptococcus cricetus* HS-6 and 3 recent clinical isolates (*Strep. cricetus* P12, *Strep. cricetus* S2 and *Strep. cricetus* S38).

² The culture collection microorganisms were kindly donated by Center for Oral Biology – University of Rochester, Rochester, NY, USA (Dr. W. H. Bowen). The clinical isolates microorganisms were kindly donated by the Oral Microbiology, FOP/UNICAMP, SP, Brazil (Dr. R. B. Gonçalves).

MIC and MBC Determinations

The antimicrobial activity was determined by minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) in accordance with Koo *et al.* (2000) and Duarte *et al.* (2003).

For MIC determination, the starting inoculum was $1-2 \times 10^5$ cfu mL⁻¹. Two-fold dilution series of extracts or fractions (concentrations ranging from 1.5 to 800 µg mL⁻¹ two folds) or negative control (80% ethanol, v/v) were tested. MIC was defined as the lowest concentration of extract or fraction that had restricted growth to a level lower than 0.05 (no visible growth). For the determination of MBC (Minimum Bactericidal Concentration), an aliquot (50 µL) of all incubated test tubes with concentrations higher than the MIC was subcultured on BHI agar supplemented with 5% of defibrinated sheep blood. The MBC was defined as the lowest concentration that enables no growth on the agar (99.9% kill). Six replicates were made for each concentration of the tested extracts for all assays.

Inhibition of adherence of growing cells to a glass surface

To assess the bacterial adherence of growing cells of mutans streptococci to a glass surface, microorganisms were grown in BHI broth plus 1% sucrose (w/v) as detailed in Koo *et al.* (2000) and Duarte *et al.* (2003). The tubes contained sub-MIC concentrations of crude extracts (EE-*Ml* and EE-*Mg*) and hexane fractions (H-*Ml* and H-*Mg*) of both *Mikania* and negative control (80% ethanol, v/v). After incubation, the adhered cells were washed, resuspended and the adhered cells were spectrophotometrically measured at 550 nm using the procedures outlined by Koo *et al.* (2000). The inhibition of adherence was defined as the lowest concentration that allowed no visible cell adherence on the glass surface. Six replicates were made for each concentration of the tested extracts for all assays.

RESULTS

The chromatograms results of GC-MS of ethanolic extract (EE) of *M. laevigata* (*Ml*) and *M. glomerata* (*Mg*) are shown in Figure 1 and Table 1. The relative percentages of identified and isolated compounds in EE, hexane fraction (H) and ethyl acetate (EA) of *Ml* and *Mg* are listed in Tables 1, 2 and 3. 22 different chemical compounds in all EE and fractions were found.

It was found that the compounds of the *M. laevigata* were qualitatively similar to *M. glomerata* (Table 1, 2 and 3), except by the coumarin, cupressenic acid, and isobutylloxigrandifloric that are present only at *M. laevigata* (Table 1, 2 and 3). In the EE-*Ml* (Table 1) the major compounds presents are the octadecen (35.65%), cupressenic acid (27.99%), coumarin (17.81%) and kaurenoic acid (17.64 %) while in EE-*Mg* kaurenoic acid (MM16) (17.94 %) and diterpenic acid (MM 316) (8.08 %) are the main identified compounds (Tables 1). The coumarin in H-*Ml* (40.08%) and the kaurenoic acid (52.47%) in the H-*Mg* are the main identified compounds (Tables 2). In ethyl acetate fraction of *M. laevigata* (EA-*Ml*) (Table 3) the major compound present is cupressenic acid (67.04%) while in *M. glomerata* (EA-*Mg*) the kaurenoic (25.03 %) and diterpenic acid (MM 316) (22.60 %) are the major compounds. Diterpenic ester derived from kaurenoic acid (MM 414) was found only at EE-*Mg* (Table 1) and H-*Mg* (Table 2).

The MIC and MBC values of EE-*Ml*, EE-*Mg*, H-*Ml*, H-*Mg* are shown in Tables 4, and the values of MIC and MBC obtained of EA-*Ml* and EA-*Mg* (200 to 400 $\mu\text{g mL}^{-1}$ MIC and higher than 800 $\mu\text{g mL}^{-1}$ MBC values) were omitted of the Table because not showed biologically effectiveness as hexane fractions. The hexane fraction of both species of *Mikania* (H-*Ml* and H-*Mg*) obtained the lowest MIC and MBC values, showing antimicrobial activities and inhibition of cell adherence against mutans streptococci at concentrations between 12.5 $\mu\text{g mL}^{-1}$ to 100 $\mu\text{g mL}^{-1}$ for MIC (Table 4), 12.5 $\mu\text{g mL}^{-1}$ to 400 $\mu\text{g mL}^{-1}$ for MBC (Table 4), and 3.125 $\mu\text{g mL}^{-1}$ to 12.5 $\mu\text{g mL}^{-1}$ ADH (Table 5).

In the MIC assay (Table 4), all extract and fractions tested showed antimicrobial activity against the tested microorganisms, except against *Strep. mutans* D1 e *Strep. mutans* P6 (clinical isolates), which growth was not inhibited only by the crude extract EE-*Ml* and EE-*Mg* at the maximum concentration tested 800 $\mu\text{g mL}^{-1}$.

In the MBC assay (Table 4), the crude extracts (EE-*Ml* and EE-*Mg*) did not show bactericidal activity against the great majority of clinical isolates microorganisms. Similarly, both EA-*Ml* and EA-*Mg* were not effective against *Strep. sobrinus* and *Strep. cricetus* clinical isolates up to the maximum concentration tested (800 $\mu\text{g mL}^{-1}$).

The values of the inhibition of mutans streptococci cell adherence to a glass surface obtained by the extracts and the fractions of *M. laevigata* and *M. glomerata* are shown in

Table 5. The values of inhibition were Sub-MIC concentrations; two-three times lower than MIC. The crude extract did not only inhibit the adherence against *Strep. sobrinus* 6715 and *S. mutans* Ingbritt 1600, as well as acted at low concentration ($25 \mu\text{g mL}^{-1}$). The lowest values of inhibition of cell adherence assays of hexane fraction were between 3.125 and $12.5 \mu\text{g mL}^{-1}$. EA-Ml and EA-Mg did not show any effect at sub-MIC levels.

DISCUSSION

It is well known that mutans streptococci have been considered the major etiological agent in dental caries. Both *Strep. mutans* and *Strep. sobrinus* synthesize extra cellular glucans and fructans from sucrose, which add to the pathogenicity of dental plaque (Hamada and Slade, 1980; Whiley and Beighton, 1998).

Therefore, antimicrobial agents against these oral pathogens, as a primary means of controlling bacterial colonization and accumulation of plaque, could play an important part in the prevention of dental caries and periodontal diseases. Thus, it is reasonable to search for natural products that have anti-plaque properties and antimicrobial activity against oral pathogens (Koo *et al.*, 2000).

In this investigation *Mikania* genus plant showed inhibition of the growth and cell adherence of mutans streptococci. Among all of the crude extracts and fractions tested of both *Mikania*, the hexane fractions were more effective to inhibit mutans streptococci growth, showing MIC values and MBC values at low concentrations. Overall, MIC and MBC values for the clinical isolated microorganisms were higher than those found for culture collection strains, demonstrating that clinical isolated microorganisms are more resistant than laboratory strains, as described by Duarte *et al.* (2003). This data are important because the laboratory strains that are commonly used to determine susceptibility to antimicrobials, may not express the same virulence or resistance level compared with strains recently isolated from the oral cavity (Duarte *et al.*, 2003). On the other hand, hexane fraction was efficient against these bacteria isolated recently.

According to Rios *et al.* (1988), natural crude extracts that have activity at concentrations lower than $100 \mu\text{g mL}^{-1}$ could have great antimicrobial potential, since the active compounds can be isolated and used at lower concentrations. Our data are relevant

because shows MIC values of hexane fraction of both *Mikania* between 12.5 and 100 $\mu\text{g/mL}^{-1}$. Besides, some compounds present in the hexane and ethyl acetate fractions can be responsible for the antimicrobial effect of the EAs fraction, justifying their lower effect than the hexane fraction, where these compounds are in larger quantity.

The compounds cumarina and cupressenic, diterpenic and kaurenoic acids, identified from the hexane fraction (non-polar fraction) of both *Mikania* (Table 2) can be responsible for the greatest antimicrobial activity of this fraction against mutans streptococci in MIC, MBC and adherence cells assays, at lower concentration. It is well established that these compounds isolated are related to antimicrobial activity. Thus, Davino *et al.* (1989) described two kaurenoic acids (kaurenoic acid and cinnamoylgrandifloric acid) have antimicrobial and antifungal activities against some pathogens. Diterpenes from the leaves of *Rabdosia trichocarpa* have been responsible for the antibacterial activity against oral microorganisms (Osawa *et al.*, 1994). Nevertheless, some compounds identified in *Mikania* samples, like cupressenic acid, have not been thoroughly investigated, and little is known about its antimicrobial activity against oral microorganisms or their effects on dental plaque formation *in vitro*.

In addition, the extracts and the fractions of *M. laevigata* and *M. glomerata* also showed *in vitro* inhibition of mutans streptococci cell adherence to a glass surface at lower concentration and sub MIC values. The results expressed in Table 3 showed that the most effective extract against mutans adherence once more was the hexane fraction of both species, confirming the effective of hexane fraction showed by lower MIC and MBC values. The inhibitory effect of these fractions on cell adherence of mutans strains can be related to their action on GTF enzyme, inhibiting glucans production, specially insoluble glucans. GTF enzymes are the main responsible for the pathogenic potential of dental plaque by promoting the adherence and accumulation of mutans streptococci on the teeth (Koo *et al.*, 2000, Duarte *et al.*, 2003). However, further studies need to be conducted to confirm the effect of the isolated compounds of these fractions on activity of individual and purified glucosyltransferase enzymes.

In conclusion, the results of the present study regarding the extracts and the purified fractions (hexane and ethyl acetate) of both species of *Mikania* showed remarkable

inhibitory activities against mutans streptococci growth and cell adherence, specially the hexane fractions that were the most effective extract against all bacterial strains. This finding implies that the pharmacologically active compounds identified from the hexane fractions (Table 2) that have non-polar characteristics, could be involved with the antimicrobial effect against mutans streptococci. Therefore, further studies should be developed in order to test these components alone and in association. In addition, the antimicrobial assay showed that the extracts and the fractions of *M. laevigata* and *M. glomerata* acted at lower concentrations and had remarkable antimicrobial activity against growth and inhibition of cell adherence on mutans streptococci.

This great inhibitory effect of *Mikania*, suggest that this plant can be useful for development of antibacterial agents against oral pathogens, being a promising anti-plaque / anti-caries agent and its identified chemical compounds need to be investigated.

REFERENCES

1. Barroso, G.M. (1986) Sistemática de angiospermas do Brasil. *Imprensa universitária*. Universidade federal de Viçosa Vol 3. *Apud* Ruas, P.M.; Ruas C.F.; Maffei, E.M.D.; Marin-Morales, M.A. and Águiar-Perecim, M.L.R. (2000) Chromosome studies in the genus *Mikania* (Asteraceae). *Genetics and Molecular Biology* 23: (4) 979-984.
2. Beghetti, A.E.; Rehder, V.L.G.; Antônio, M.; Carvalho, J.E. (2004) Antiulcerogenic activity of crude hydroalcoholic extract and coumarin isolated from *Mikania laevigata* Schultz Bip. *Phytomedicine*, in press.
3. Cai, L. and Wu, C.D. (1996) Compounds from *Syzygium aromaticum* possessing growth inhibitory activity against oral pathogens. *J. Nat. Prod.*, 59: 987-90.
4. Corrêa, M.P. (1942) Dicionário de plantas úteis do Brasil e das exóticas cultivadas. *Ministério da Agricultura* 3: 517-20.
5. Cragg, G.M.; Newman D.J.; Snader K.M. (1997) Natural products in drug discovery and development. *J. Nat. Prod.* 60:52-60.
6. Davino, S.C.; Giesbrecht, A.M.; Roque, N.F. (1989) Antimicrobial activity of kaurenoic acid derivatives substituted on carbon – 15. *Braz. J. Med. Biol. Res.*, 22(9): 1127-9.


7. de Moura, R.S.; Costa, S.S.; Jansen, J.M.; Silva, C.A.; Lopes, C.S.; Bernardo-Filho, M.; da Silva, V.N.; Criddle, D.N.; Portela, B.N.; Rubenich, L.M.S.; Araujo, R.G. and Carvalho, L.C. (2002) Bronchodilator activity of *Mikania glomerata* Sprengel on human bronchi and guinea-pig trachea *Journal of Pharmacy and Pharmacology*. 54, (2) 249-256.
8. Duarte, S.; Koo, H.; Bowen, W.H.; Hayacibara, M.F.; Cury, J.A.; Ikegaki, M.; Rosalen, P.L. (2003) Effect of a Novel Type os Propolis and Its Chemical Fraction on Glucosyltransferases and on Growth and Adherence of Mutans Streptococci. *Biol. Pharm. Bull.* 26(4), 527-531.
9. Fabbri, H.; de Oliveira, D.R.; Vichnewski, W. and Herz, W. (1997) Diterpenes of *Mikania lindbergii* Baker. *Biochemical Systematics and Ecology* 25, (6) 563-564.
10. Fierro, I.M.; da Silva, A.C.B.; Lopes, C.D.; de Moura, R.S.; Barja-Fidalgo, C. (1999) Studies on the anti-allergic activity of *Mikania glomerata*. *Journal of Ethnopharmacology*. 66: (1) 19-24.
11. King, R.M. and Robinson, H. (1987) The genera of the Eupatoriae (Asteraceae) *Monographs in Systematic Botany*. Missouri Botanical Garden. 22
12. Koo, H.; Pearson. S.K.; Scott-Anne, K.; Abranches, J.; Cury, J.A.; Rosalen, P.L.; Park, Y.K.; Marquis, R.E. and Bowen, W.H. Effects of apigenin and *tt*-farnesol on glucosyltransferase activity, biofilm viability and caries development in rats. *Oral Microbiol Immunol*. 2002 Dec; 17(6): 337-43.
13. Koo, H.; Rosalen, P. L.; Cury, J. A. *et al.* (1999). Effect of *Apis mellifera* propolis from two Brazilian regions on caries development in desalivated rats. *Caries Research* **33**, 393-400.
14. Limberger, R.P.; Aboy, A.L.; Bassani, V.L.; Moreno, P.R.H.; Ritter, M.R.; Henriques, A.T. (2001) Essential oils from four *Mikania* species (Asteraceae). *Journal of Essential Oil Research*. 13: (4)225-228.
15. Loesche, W.J. (1986) Role of *Streptococcus mutans* in human dental decay. *Mictrobiol Ver.* 50, 353-380.

16. Osawa, K.; Yasuda, H.; Maruyama, T.; Morita, H.; Takeya, K.; Itokawa, H. (1992) Isoflavanones from the heartwood of *Swartzia polyphylla* and their antibacterial activity against cariogenic bacteria. *Chem. Pharm. Bull.*, 40: 2970-4.
17. Park, Y.K. and Ikegaki, M. (1998) Evaluation of ethanolic extracts of propolis from Brazil and Korea by physiochemical and biological methods. *Korean J. Apic*, 13(1): 27-34.
18. Paul, R.K.; Jabbar, A., Rashid, M.A. (2000) Antiulcer activity of *Mikania cordata*. *Fitoterapia* 71(6): 701-3.
19. Pereira, N.A.; Pereira, B.M.; do Nascimento, M.C.; Parente, J.P.; Mors, W.B. (1994) Pharmacological screening of plants recommended by folk medicine as snake venom antidotes; IV. Protection against jararaca venom by isolated constituents. *Planta Med*, 60 (2), 99-100.
20. Rios, J.L.; Recio, M.C. and Villar A. (1988) Screening methods for natural products with antimicrobial activity: a review of the literature. *J. Ethnopharmacol.* 23, 127-149.
21. Ruppelt, B.M.; Perreira, E.F.; Gonçalves, L.C.; Pereira, N.A. (1991) Pharmacological screening of plants recommended by folk medicine as anti-snake venom – I. Analgesic and anti-inflammatory activities. *Mem. Inst. Oswaldo Cruz*, 86, Suppl 2:203-5.
22. Schilling, K. M. and Bowen, W. H. (1992). Glucans synthesized *in situ* in experimental salivary pellicle function as specific binding sites for *Streptococcus mutans*. *Infection and Immunity* 60, 284-295.
23. Tanzer, J. M.; Freedman, M. L.; Fitzgerald, R. J. *et al.* (1985). Virulence of mutants defective in glucosyltransferase, dextran-mediated aggregation, or dextranase activity. In *Molecular Basis of Oral Microbial Adhesion*, (Mergenhagen, S. E. & Rosan, B., Eds), pp. 204-211. American Society for Microbiology, Washington, DC, USA. Hamada, S. and Slade, H.D. (1980) Biology, immunology and cariogenicity of *Streptococcus mutans*. *Microbiol. Rev.* 44:331-384.
24. Vilegas, J.H.Y.; de Marchi, E.; Lanças F.M. (1997). Extraction of low-polarity compounds (with emphasis on coumarin and kaurenoic acid) from *Mikania glomerata* (guaco) leaves. *Phytochemical Analysis* 8, 266-270.


25. Whiley, R.A. and Beighton, D. (1998) Current classification of the oral streptococci. *Oral Microbiol Immunol*; 13: 195-216.
26. Wu-Yuan, C.D.; Chen, C.Y.; Wu, R.T. (1988) Gallotannins inhibit growth, water-insoluble glucan synthesis and aggregation of mutans streptococci. *J. Dent. Res.*, 67: 51-5.
27. Yatsuda, R.; Murata, R.M.; Duarte, S.; Rosalen, P.L.; Cury, J.A.; Rehder, V.G. and Koo, H. (2001) Antimicrobial effect of *Mikania* against *Streptococcus mutans*. *Pesquisa Odontológica Brasileira*. 15: SET (I103) p34
28. Yatsuda, R.; Murata, R.M.; Duarte, S.; Cury, J.A.; Rehder, V.G.; Koo, H. and Rosalen, P.L. (2002) Effect of *Mikania* genus plant on the growth and cell adherence of mutans streptococci. *J. Dent. Res.* 81: March (special issue A) A-272, 2117.

FIGURE

Figure 1– Chromatograms of methylated hydroalcoholic extract of *M. laevigata* and *M. glomerata*.



- 1= Dihydrocoumarine
- 2= Coumarine
- 3= Spathulenol
- 4= Hexadecanoic acid
- 5= 9,12-Octadecadienoic acid
- 6= 9,12,15-Octadecatrienoic acid
- 7= Cupreseni acid
- 8= Kaurenoic acid



- 4= Hexadecanoic acid
- 6=9,12,15-Octadecatrienoic acid
- 8= Kaurenoic acid
- 9= Octadecene
- 10= Diterpenic acid
- 11= Grandifloric acid

TABLES

Table 1: Relative percentage of the identified compounds by Gas chromatography (GC-MS) of the ethanolic extract of *M. laevigata* (EE- *MI*) and *M. glomerata* (EE-*Mg*).

	Isolated and identified compounds	Time. (Min.)	Relative %
Hydroalcoholic extract of <i>M. laevigata</i> (EE- <i>MI</i>)	Dihydrocoumarin	11.43	1.93
	Coumarin	12.90	17.81
	Spathulenol	16.19	4.56
	Hexadecanoic acid	23.55	9.23
	Cupressenic acid	29.21	27.99
	Kaurenol	30.32	4.46
	Kaurenoic acid	31.26	17.64
	Isopropiloxi-grandifloric acid	38.51	3.75
	Isobutiloxi-grandiflorico acid	39.99	0.59
	2,5-Ciclohexadiene-1,4-dione,2,6-bis	13.38	3.68
	Hexadecanoic acid	23.62	5.06
	1-Octadecene	27.02	35.65
Hydroalcoholic extract of <i>M.</i> <i>glomerata</i> (EE- <i>Mg</i>)	9,12,15- Octadecatrienoic acid	27.27	2.37
	Octadecanoic acid	27.64	3.78
	Kaurenoic acid (MM 316)	31.43	17.94
	Diterpenic acid (MM 316)	32.23	8.08
	Grandifloric acid (MM 332)	35.26	1.42
	Isopropiloxi-grandifloric acid	40.10	0.45
	Diterpenic acid (MM 414)	41.65	0.65

Table 2: Relative percentage of the identified compounds by Gas chromatography (GC-MS) of the methylated hexane fraction (H- *MI*) of *M. laevigata* and *M. glomerata* (H-*Mg*).

	Isolated and identified compounds	Time (Min.)	Relative %
Methylated hexane fraction (H- <i>MI</i>) of <i>M. laevigata</i>	Dihydrocoumarin	11.56	1.75
	Coumarin	13.44	40.08
	Spathulenol	16.37	6.17
	Hexadecanoic acid	23.70	9.65
	9,12-Octadecadienoic acid	27.11	3.04
	9,12,15-Octadecatrioneic acid	27.26	3.38
	Cupressenic acid	29.33	7.60
	Kaurenol	30.49	1.83
	Kaurenoic acid	31.39	4.92
	Isopropiloxi-grandifloric acid	38.65	1.40
	Isobutiloxi-grandifloric acid	40.13	0.40
Methylated hexane fraction (H- <i>Mg</i>) of <i>M. glomerata</i>	Spathulenol	12.83	3.03
	Caryophyllene Oxide	12.97	2.84
	Hexadecanoic acid	20.27	12.17
	10,13- Octadecadienoic acid	23.59	6.99
	9,12- Octadecadienoic acid	23.75	10.28
	Kaurenoic acid	27.54	52.47
	Diterpenic acid (MM 316)	28.24	4.13
	Grandifloric acid	31.29	3.42
	Isopropilóxi-grandifloric acid	36.20	1.66
	Diterpenic ester (MM 414)	37.64	2.99

Table 3: Relative percentage of the identified compounds by Gas chromatography (GC-MS) of the methylated ethyl acetate fraction (EA- *MI*) of *M. laevigata* and *M. glomerata* (EA-*Mg*).

Isolated and identified compounds		Time (Min.)	Relative %
Methylated ethyl acetate fraction (EA- <i>MI</i>) of <i>M. laevigata</i>	Hexadecanoic acid	20.13	10.66
	9,12-Octadecadienoic acid	23.43	2.29
	9,12,15-Octadecatrienoic acid	23.56	3.03
	Cupressenic acid	27.35	67.04
	Kaurenoic acid	28.11	9.62
Methylated ethyl acetate fraction (EA- <i>Mg</i>) of <i>M. glomerata</i>	Trans-Cariofilene	12.32	2.44
	EI-Bicyclosiquiphellandrene	13.81	4.57
	Spathulenol	16.17	2.50
	Hexadecanoic acid	23.54	7.93
	8,11- Octadecadienoic acid	26.97	4.52
	9,12,15- Octadecatrienoic acid	27.14	11.34
	Kaurenoic acid	31.27	22.60
	Diterpenic acid (MM 316)	32.14	25.03

Table 4: Values of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of crude extracts (EE-*Ml* and EE-*Mg*), hexane fractions (H-*Ml* and H-*Mg*), and ethyl acetate fractions (EA-*Ml* and EA-*Mg*) of both *Mikania*, against the mutans streptococci strains.

<i>MICROORGANISMS</i>	Crude extract				Hexane			
	EE- <i>Ml</i>		EE- <i>Mg</i>		H- <i>Ml</i>		H- <i>Mg</i>	
	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC
<i>Strep. mutans</i> Ingbritt 1600	25	50	25	50	12.5	12.5	12.5	25
<i>Strep. mutans</i> OMZ 175	200	400	100	400	100	100	25	400
<i>Strep. mutans</i> D1*	> 800	> 800	> 800	> 800	50	50	12.5	100
<i>Strep. mutans</i> P20*	200	> 800	200	> 800	25	25	25	50
<i>Strep. mutans</i> P6*	> 800	> 800	> 800	> 800	50	50	25	100
<i>Strep. sobrinus</i> 6175	25	50	25	100	12.5	12.5	12.5	25
<i>Strep. sobrinus</i> P7*	200	> 800	200	> 800	12.5	12.5	12.5	50
<i>Strep. sobrinus</i> S2*	100	400	200	400	25	25	12.5	50
<i>Strep. sobrinus</i> S17*	100	> 800	100	> 800	12.5	12.5	12.5	25
<i>Strep. cricetus</i> HS-6	100	100	50	200	12.5	12.5	12.5	200
<i>Strep. cricetus</i> P12*	100	400	200	> 800	25	25	25	50
<i>Strep. cricetus</i> S2*	100	> 800	100	> 800	50	50	25	50
<i>Strep. cricetus</i> S38*	100	> 800	100	> 800	50	50	12.5	50

* Recent clinical isolate microorganism. MIC values are expressed in $\mu\text{g mL}^{-1}$. The concentrations of extracts and fractions ranged from 1.5- 800 $\mu\text{g mL}^{-1}$. (n=12)

Table 5: Effect of crude extracts of both *Mikania* (EE-*Ml* and EE-*Mg*) and hexane fractions (H-*Ml* and H-*Mg*) on adherence of growing cells of mutans streptococci strains.

MICROORGANISMS	Cell Adherence ($\mu\text{g mL}^{-1}$)			
	EE- <i>Ml</i>	EE- <i>Mg</i>	H- <i>Ml</i>	H- <i>Mg</i>
<i>Strep. mutans</i> Ingbritt 1600	25	25	3.125	3.125
<i>Strep. mutans</i> OMZ 175	50	100	6.25	6.25
<i>Strep. mutans</i> P20*	400	400	3.125	3.125
<i>Strep. mutans</i> P6*	400	400	3.125	3.125
<i>Strep. mutans</i> D1*	400	400	3.125	3.125
<i>Strep. sobrinus</i> 6175	25	25	3.125	3.125
<i>Strep. sobrinus</i> P7*	100	100	3.125	3.125
<i>Strep. sobrinus</i> S2*	100	100	3.125	3.125
<i>Strep. sobrinus</i> S17*	100	100	3.125	3.125
<i>Strep. cricetus</i> HS-6	50	50	12.5	12.5
<i>Strep. cricetus</i> P12*	50	100	12.5	12.5
<i>Strep. cricetus</i> S2*	50	100	12.5	12.5
<i>Strep. cricetus</i> S38*	50	100	12.5	12.5

* Recent clinical isolate microorganism.

^a The Cell adherence values are expressed in $\mu\text{g mL}^{-1}$. The concentrations of extracts and fractions ranged from 1.5 - 800 $\mu\text{g mL}^{-1}$.

¹. (n=12)

2.2. Estudo 2

Title: “Antimicrobial activity of compounds isolated from *Mikania sp.* on mutans streptococci biofilms”.

Regiane Yatsuda^{a*}, Jaime A. Cury^a, Vera L. G. Rehder^c, Leandro V. Melo^c, Ramiro M. Murata^a, Simone Duarte^a, William. H. Bowen^b, Robert E. Marquis^b, Pedro L. Rosalen^a and Hyun Koo^b

^a Department of Physiological Sciences, Faculty of Dentistry of Piracicaba, State University of Campinas (UNICAMP), SP, Brazil.

^b Center for Oral Biology and Eastman Department of Dentistry, University of Rochester Medical Center, Rochester, New York, USA

^c Multidisciplinary Center of Chemical, Biological and Agricultural Researches, CPQBA/ UNICAMP, Brazil.

* Regiane Yatsuda

Faculty of Dentistry of Piracicaba, State University of Campinas,

Department of Physiological Sciences

Caixa Postal 52, 13414-900

Piracicaba, SP, Brazil

Tel.: (55) 19-34125313

e-mail: rosalen@fop.unicamp.br or reyatsuda@yahoo.com

ABSTRACT

The aim of this study was to evaluate the influence of the compounds isolated from hexane fractions of *Mikania glomerata* and *Mikania laevigata* on the viability, accumulation and polysaccharide composition of mutans streptococci (*Streptococcus mutans* UA159 and *S. sobrinus* 6715) biofilms. We also explored their influence on the activity of surface-adsorbed glucosyltransferases (GTFs). ent-kaur-16-en-19-oic acid (**1**) and ent-beyer-15-en-19-oic acid (**2**) (from *M. laevigata*), and (**1**) diterpenic acid (**3**) (from *M. glomerata*) were isolated and identified from the hexane fractions by spectroscopic methods. In general, the isolated compounds displayed bactericidal activity against *S. mutans* and *S. sobrinus* biofilms, especially diterpenic acid (at 250 µg/mL) and ent-beyer-15-en-19-oic acid (**2**) (at 500 µg/mL) acids. The biomass (dry-weight) of the biofilms treated with compounds (**3**) (250 µg/mL) and (**2**) (500 µg/mL) acids were significantly less than those treated with vehicle control (10% ethanol, vol./vol.) ($P<0.05$). Furthermore, the insoluble polysaccharide content of the treated-biofilms was significantly affected. Kaurenoic acid exhibited modest inhibitory actions compared to other test agents. Our data showed that compounds from *M. glomerata* and *M. laevigata* were effective against mutans streptococci biofilms; diterpenic acid is a promising novel natural compound for biofilm control.

KEYWORDS: *Mikania* sp., diterpenic acid, mutans streptococci, biofilm, glucosyltransferases.

INTRODUCTION

The ability of mutans streptococci to produce extracellular polysaccharides, mainly glucans, has been recognized as a critical factor in the pathogenesis of dental caries, and also plaque formation and accumulation (Gibbons and Van Houte, 1975; Hamada e Slade, 1980; Tanzer *et al.*, 1985; Loesche, 1986; Yamashita *et al.*, 1993). Glucans, synthesized from dietary sucrose by glucosyltransferases (GTFs), are essential for the adherence and accumulation of *Streptococcus mutans* and other oral microorganisms to the tooth surface, leading to the formation of cariogenic biofilm communities (Tanzer *et al.*, 1985; Schilling and Bowen, 1992; Marsh and Bradshaw, 1995). Therefore, mutans streptococci and/or the GTFs should be prime targets for any therapeutic agent aimed at prevention of dental biofilm-related diseases, such as caries and periodontal diseases.

Natural products have been one of the most successful sources for the discovery of novel therapeutic agents (Cragg *et al.*, 1997; Harvey 2001). Among various plant extracts used in Brazilian folk-medicine, the ones from *Mikania* genus plant (a sub-scrub creeper of woody branches known popularly as “guaco”) are of particular interest due to multiple pharmacological properties, such as anti-inflammatory and antimicrobial activities (Ruppelt *et al.*, 1991; Correa, 1942; Pereira *et al.*, 1994; Celeghini *et al.*, 2001, Yatsuda *et al.*, 2001, 2002). Furthermore, our previous studies have shown that hexane fractions of *M. laevigata* and *M. glomerata*, exhibit antimicrobial activity against planktonic cells of mutans streptococci (Yatsuda *et al.*, 2000, 2001). The major components in the hexane fractions were coumarin, and ent-kaur-15-en-19-oic acid (**1**), ent-beyer-15-en-19-oic acid (**2**), diterpenic acid (**3**) and decanoic acid (Yatsuda *et al.*, unpublished).

Recently, we explored the antibacterial activity of several chemical compounds isolated from the hexane fraction of both *Mikania* species. Among them, ent-kaur-16-en-19-oic acid (**1**) and ent-beyer-15-en-19-oic acid (**2**) (from *M. laevigata*), and ent-kaur-16-en-19-oic acid (**1**) and diterpenic acid (**3**) (from *M. glomerata*) inhibited the growth of the planktonic cells of mutans streptococci at low concentrations (MIC 5, 2.5 and 10 µg/mL, respectively (Yatsuda *et al.*, unpublished).

Considering the promising antibacterial effects of the compounds from *M. laevigata* and *M. glomerata*, the purpose of this study was to evaluate the influence of these agents on

the viability, accumulation and polysaccharide composition of mutans streptococci biofilms.

MATERIALS AND METHODS

Plant material and chemical studies

In this study, the compounds from hexane fraction of *M. laevigata* (*MI*) and *M. glomerata* (*Mg*) were isolated and identified. The aerial parts of *Mikania laevigata* Schultz Bip. and *Mikania glomerata* Sprengel were collected from Experimental field of the Pluridisciplinar Center of Chemical, Biological and Agricultural Researches - CPQBA/UNICAMP, Campinas, SP. Voucher specimen of *M. laevigata* (*MI*) and *M. glomerata* (*Mg*) is deposited at Herbarium of Biology Institute of Unicamp at Campinas under number UEC - 102.046 and UEC 102047, respectively.

Extraction and isolation

Dried and pulverized leaves from *M. laevigata* and *M. glomerata* (400 g) were extracted 2 X with ethanol: water (70:30) at room temperature to give 79.1 g and 58.2 g of crude extracts of the *M. laevigata* (EE-*MI*) and of the *M. glomerata* (EE-*Mg*). 40 g of the extracts were fractionated with hexane for three times in dispersor Ultra-Turrax obtaining the hexane fractions of *M. laevigata* H-*MI* (5.6 g) and *M. glomerata* H-*Mg* (5.2 g), respectively. The fractions H-*MI* and H-*Mg* were fractionated separately in dried column chromatography (cellulose 2 X 30 cm) using Si gel 60 with mixtures of chloroform and EtOAc (70:30). The column were cut in four parts and extracted with chloroform supplying 4 fractions: H1-*MI* (0.45 g), H2-*MI* (1.80 g), H3-*MI* (1.86 g), H4-*MI* (1.50 g); and H1-*Mg* (0.70 g), H2-*Mg* (1.65 g), H3-*Mg* (1.78 g), and H4-*Mg* (1.35 g). The fractions were monitored by TLC using hexane-AcOEt (80:20).

The fraction F2H-*Ml* was purified in column with sílica gel 60 (0.063-0200 mm) impregnated with AgNO₃ using hexane:AcOEt in polarity gradient. 72 fractions were collected and monitored by TLC allowing to isolate 430 mg of the ent-kaur-16-en-19-oic acid (**1**), 195 mg of the ent-beyer-15-en-19-oic acid (**2**) and 68 mg of the mixture of others diterpenic acids.

The fractions H2-*Mg* and H3-*Mg* were grouped and purified on flash column with Si gel 60 (230-400 mesh) by eluting with hexane and gradually increasing the polarity with EtOAc. Sixty fractions were collected and monitored by TLC. The fraction eluted with hexane-AcOEt (80:20) allowing isolating 350 mg of the ent-kaur-16-en-19-oic acid (**1**) and 64 mg of other diterpenic acid (**3**).

The compounds isolated were crystallized in hexane and those structures were confirmed by comparing physical and spectroscopic properties, including ¹H; ¹³C-NMR and MS spectra, with those reported in the literature; i.e. for (**1**) (Cruz *et al.*, 1992., Ohno *et al.*, 1979); (**2**) (Takahashi, *et al.*, 2001., Bohlmann *et al.*, 1976); (**3**) (Castro, *et al.*, 1985). Optical rotation was measured with a Perkin-Elmer polarimeter, Melting points (Mp's) were determined on a Koffler boot place and comparison with the data.

Test agents. The concentrations of the isolated compounds used in this study were 1, 10 and 100 times of their MIC values. The biofilms were treated with cupressenic acid (5 µg/mL; 50 µg/mL and 500 µg/mL), diterpenic acid (2.5 µg/mL; 25 µg/mL and 250 µg/mL) and kaurenoic acid (10 µg/mL; 100 µg/mL and 1000 µg/mL). Vehicle control (ethanol 10% v/v) was used as a negative control.

Bacterial strains. The bacterial strains used in this study were *Streptococcus mutans* UA159 and *S. sobrinus* 6715, which are proven virulent cariogenic pathogens (Ajdic *et al.*, 2002). For the production of GTFs, the following constructs were used: *S. milleri* KSB8, which harbors the *gtfB* gene (for GTF B production) and *S. mutans* WHB410, which only expresses *gtfC* gene (for GTF C production).

Preparation of the biofilms. Biofilms were formed on standard glass microscope slides (Micro slides, Glass Técnica Com., São Paulo, SP, Brazil) in batch cultures for 5 days as detailed elsewhere (Ma *et al.*, 1999; Koo *et al.*, 2003). Typically, 5-day-old biofilms yield approximately 10⁸ colony forming units (CFU) per mm² of slide (Ma *et al.*,

1999).

Time-kill assays. The killing assays were performed according to Koo *et al.* (2003). Briefly, 5 day-old biofilms were exposed to the test compounds (at 1, 10 and 100 times MIC) or vehicle control (10% ethanol, v/v). At specific intervals, the biofilms were removed, suspended and subjected to sonication as detailed in Koo *et al.* (2003). The homogenized suspension was serially diluted (10^{-1} to 10^{-5}) and plated on tryptic soy agar (Oxoid LTD, Basingstoke, UK) by means of a spiral plater (Whitley Automatic Spiral Plater, DW Scientific). The plates were incubated at 10% CO₂ at 37 °C for 48 h, and then the number of colony forming units per mL (CFU/mL) was determined. Killing curves were constructed by plotting values in the ordinate label, N₀ stands for the original number of CFU/mL and N stands for the number after the indicated times of exposure. All of the assays were carried out in quadruplicate on at least three different times. A bactericidal effect was defined as a $> 3 \log N/N_0$ decreased in the CFU/mL from initial viable counts, at time zero (Koo *et al.*, 2002). The potential for drug carryover to produce false low viability counts was minimized by: 1) washing biofilm slides in salt solution (6 times), 2) dilution of inocula, 3) plating small volumes of diluted samples (50 µl).

Inhibition of biofilm formation. The biofilms were grown for 48 h to allow initial bacterial deposition. At this point (48 h old), the biofilms were treated twice daily (one-minute exposure) until the 5th day of the experimental period (120 h-old biofilms) with each of the test compounds (at 1, 10 and 100 times MIC) or vehicle control as described by Koo *et al.* (2003); each biofilm was exposed to the respective treatment six times. Biofilm assays were performed in quadruplicate in at least 3 different experiments. At the end of the experimental period, the biofilms were removed and sonicated; the homogenized suspension was used for dry-weight (biomass), total protein, bacterial viability and polysaccharide analyses as detailed elsewhere (Koo *et al.*, 2003). Total protein of the suspension was determined by the method of Lowry (Lowry *et al.*, 1951) using bovine serum albumin to construct the standard curve. For the bacterial viability, an aliquot (0.1 mL) of the homogenized suspension was serially diluted (10^{-1} to 10^{-5}), plated, and the number of CFU determined as described previously. The insoluble polysaccharides were extracted and quantified as detailed elsewhere (Cury *et al.*, 2000; Koo *et al.*, 2003). All of

the assays were carried out in quadruplicate on at least three different times.

Statistical analyses. The data were analyzed using one-way analysis of variance (ANOVA), pairwise comparison was made between all the groups using Tukey-Kramer HSD method to adjust for multiple comparisons, using statistical software JMP version 3.1 (SAS Institute Inc., 1989). When no parametric data was found, Kruskal- Wallis test was used to compare all pairs in the statistical software BioEstat 3.0 (2003). The level of significance was at 5% to both tests.

RESULTS

Figure 1 the chemical structure of the compounds ent-kaur-16-en-19-oic acid (**1**), ent-beyer-15-en-19-oic acid (**2**) isolated from H2-*Ml* while the compounds (**1**) and diterpenic acid (**3**) isolated from H2-*Mg*.

The concentrations used for the test compounds in this study were 1, 10 and 100 times MIC; in general, only the compounds at 100 times MIC displayed significant inhibitory activities compared to control, and their results were shown as follows.

The results of time-kill studies for *S. mutans* UA 159 and *S. sobrinus* 6715 are shown in Figure 2 and 3. Figure 2 shows that diterpenic acid (**3**) and ent-beyer-15-en-19-oic acid (**2**) at 100 times MIC (250 µg/mL and 500 µg/mL respectively) rapidly reduced the viable counts of *S. mutans* within 1 h of treatment ($> 1 \log N/N_0$); after 4 h these compounds showed bactericidal effects ($> 3 \log N/N_0$). The viability of *S. sobrinus* biofilms was also reduced after 4 h (between 1 and 3 log N/N_0) of treatment with tested agents at 100 x MIC. The lower concentration of the agents (1 and 10 x times MIC) showed negligible effects.

For the biofilm accumulation experiment, only the compounds at 100 X MIC showed significant inhibitory effects. The data of the recoverable viable cells from biofilms treated with the test agents (twice daily, one-minute exposure) are shown in Figure 4 and 5. Figure 4 shows that the test agents slightly reduced the number of recoverable viable cells compared to those treated with the vehicle control (0.5 to 0.7 log N/N_0). Similar results were obtained for *S. sobrinus* biofilms as shown in figure 5.

All the agents tested at 100 times MIC significantly reduced the biomass of both *S. mutans* and *S. sobrinus* biofilms compared to control group ($p < 0.05$), except to ent-kaur-16-en-19-oic acid (**1**) as shown in Table 1.

Table 1 shows the total amount of insoluble polysaccharide and protein in *S. mutans* biofilms. The diterpenic acid (**3**) (250 $\mu\text{g/mL}$) was the only agent to significantly reduce the amount of polysaccharide in biofilms compared to control group ($p < 0.05$). Ent-beyer-15-en-19-oic acid (**2**) (500 $\mu\text{g/mL}$) and diterpenic acid (**3**) (250 $\mu\text{g/mL}$) also reduced the total amount of protein in the biofilms. Regarding *S. sobrinus* biofilms, total amount of polysaccharide was significantly reduced by the ent-beyer-15-en-19-oic acid (**2**) (500 $\mu\text{g/mL}$) and diterpenic acid (**3**) (250 $\mu\text{g/mL}$) compared to control group ($p < 0.05$); total protein was lower only in biofilms treated with diterpenic acid (**3**) (250 $\mu\text{g/mL}$). Ent-kaur-16-en-19-oic acid (**1**) was not able to affect significantly the amount of polysaccharide and protein in the biofilms compared to control ($p > 0.05$).

DISCUSSION

According to Harvey (2000), the access to biodiversity is fundamental for expanding the range of natural products to be used in the search for new drugs. In this context, *Mikania sp.*, a relatively unexplored natural product, could be a valuable source for exploration of novel bioactive compounds because *Mikania laevigata* and *M. glomerata* extracts showed remarkable inhibitory effects against mutans streptococci (Yatsuda *et al.*, 2001, 2002). In this study, we identified ent-kaur-16-en-19-oic acid (**1**) and ent-beyer-15-en-19-oic acid (**2**) from *M. laevigata* (H2-Ml) and diterpenic acid (**3**) and ent-kaur-16-en-19-oic acid (**1**) from *M. glomerata* (H2-Mg) as putative novel and active compounds against *S. mutans* and *S. sobrinus* biofilms.

Dental plaque is essentially a biofilm, a population of microorganisms growing on a surface and enclosed in an exopolysaccharide matrix (e.g. glucans) (Lewis, 2001). Furthermore, organisms growing in biofilm mode (sessile bacterial communities) are more resistant than these same organisms in planktonic state (Lewis, 2001). Therefore, it is desirable that potentially novel therapeutic agents aimed at preventing plaque-related oral

diseases present significant influence on the development of the biofilms, and also on glucan-producing GTF enzymes.

The findings of the present study confirm the antimicrobial potential of *Mikania* genus plant; the isolated compounds, cupressenic and diterpenic acids, were effective in reducing the accumulation and insoluble polysaccharide content of mutans streptococci biofilms. Ent-beyer-15-en-19-oic acid (**2**) and diterpenic acid (**3**) are active compounds of *Mikania* extracts.

The diterpenic acid (**3**) was the most effective compound tested reducing both the viability of the biofilms and its insoluble polysaccharide content. This finding is in agreement with in an investigation of diterpenes from the leaves of *Rabdosia trichocarpa* and their antibacterial activity against oral microorganisms, some of these compounds possess potent antibacterial activity, indicating that these diterpenes may be useful natural substances for the maintenance of oral health (Osawa *et al.*, 1994). In addition, Rehder (2001)¹ shows that diterpenic compounds isolated from *Mikania* fractions have antimicrobial activity against some microorganisms, such as *Micrococcus luteus*, *Staphylococcus aureus* and *Bacillus Subtilis*. The ent-beyer-15-en-19-oic acid (**2**) also affected the viability, accumulation and the polysaccharide and protein content of the biofilms. This finding is the first to describe the biological effects of ent-beyer-15-en-19-oic acid (**2**) against microorganisms, and need further investigation. The ent-kaur-16-en-19-oic acid (**1**) exhibited some biological effects against biofilms, although it was not as effect as diterpenic (**3**) and ent-beyer-15-en-19-oic acid (**2**).

Our findings suggest that ent-beyer-15-en-19-oic acid (**2**) and diterpenic (**3**) are promising compounds for development of therapeutic agents for plaque-related diseases. Further studies using *in vivo* models should be conducted in order to evaluate their potential as anti-caries and anti-plaque agents. We are currently pursuing the putative mechanisms of action of these natural compounds.

ACKNOWLEDGMENTS

We are grateful to Flávia da Silva for technical assistance. This research was supported by Brazilian Government Agency, FAPESP (01/11809-8, 02/13972-6).

REFERENCES

1. Bohlmann, F., M. Ahmed, N. Borthakur, M. Wallmeyer, J. Jakupovic, R.M. King, and H. Robinson. 1982. Diterpenes related to grindelic acid and further constituents from *Grindelia* species. *Phytochemistry* 21:167-172.
2. Brissette, J. L., Cabacungan, E.A., Pieringer, R.A. (1986) Studies on the antibacterial activity of dodecylglycerol, its limited metabolism and inhibition of glycerolipid and lipoteichoic acid biosynthesis in *Streptococcus mutans* BHT. *J. Biol. Chem.* 261:6338-6345.
3. Burne, R.A., Chen, Y. Y., Wexler, D. L. *et al.* (1996). Cariogenicity of *Streptococcus mutans* strains with defects in fructan metabolism assessed in a program-fed specific-pathogen-free rat model. *Journal of Dental Research* 75, 1572-1577.
4. Corrêa, M.P. (1942) Dicionário de plantas úteis do brasil e das exóticas cultivadas. *Ministério da Agricultura* 3: 517-20.
5. Cragg, G.M., Newman D.J., Snader K.M. (1997) Natural products in drug discovery and development. *J. Nat. Prod.* 60:52-60.
6. Cruz, F.G., Roque, N.F. (1992) Diterpene acids from *Mikania-triangularis*. *Phytochemistry* 31: 2793-2796.
7. Cury, J.A., Rebello, M.A.B., Del Bel Cury, A.A., Derbyshire, M.T.V.C., Tabchoury, C.P.M. (2000) Biochemical Composition and Cariogenicity of Dental Plaque Formed in the Presence of Sucrose or Glucose and Fructose. *Caries Res.* 34: 491-497.
8. Dubois M., Gilles, K.A., Hamilton, J.K. *et al.* (1956) Colorimetric method for determination of sugars and related substances. *Anal. Chem.* 28, 350-6.
9. Gibbons, R. J. and Van Houte, J. (1975). Bacterial adherence in oral microbial ecology. *Annu. Rev. Microbiol.* 29:19-44.

¹ Rehder, Vera Lúcia Garcia. CPQBA 2001 [Unpublished data, personal communication].

10. Gilbert, P., ds, J., Foley, I. (1997) Biofilm susceptibility to antimicrobials. *Adv Dent Res.* 11: 160-7.
11. Hamada, S. and Slade, H.D. (1980) Biology, immunology and cariogenicity of *Streptococcus mutans*. *Microbiol. Rev.* 44:331-384.
12. Harvey, A. (2000) Strategies for discovering drugs from previously unexplored natural products. *Drug Discov.* 5: 294-300.
13. Harvey, A. (2001) Strategies for discovering drugs from previously unexplored natural products. *Drug Discov.* 5:294-300.
14. Jacquelin, L. F., Brisset, L., Lemagrex, E., Carquin, J., Gelle, M.P., Choisy, C., (1995) Prevention of carcinogenic dental plaque. Study of the structures implicated in the *Streptococcus mutans* and *Streptococcus sobrinus* adhesion and coaggregation. *Pathol. Biol.* 43:371-379.
15. Koo H, Pearson SK, Scott-Anne K, Abranches J, Cury JA, Rosalen PL, Park YK, Marquis RE, Bowen WH. Effects of apigenin and tt-farnesol on glucosyltransferase activity, biofilm viability and caries development in rats. *Oral Microbiol Immunol.* 17(6): 337-43. (2002).
16. Koo, H, Hayacibara, B.D., Schobel, B.D., Rosalen, P.L., Cury, J.A., Park, Y.K., Vacca-Smith, A.M., Bowen, W.H. Inhibition of *Streptococcus mutans* biofilm accumulation and polysaccharide production by apigenin and tt-farnesol. *J. Antimicrobial Chemotherapy* 46, 1302–1309. (2003)
17. Koo, H., Gomes, B.P.F.A., Rosalen, P.L., Ambrosano, G.M.B., Park, Y.K. and Cury, J.A. (2000) In vitro antimicrobial activity of propolis and Arnica montana against oral pathogens. *Archives of Oral Biology* 45, 141-148.
18. Kubo, I., Muroi, H., Himejima, M. (1992) Antimicrobial activity of green tea flavor components and their combination effects. *J. Agric. Food Chem.* 40:245-248.
19. Kubo, I., Muroi, H., Kubo, A. (1993) Antimicrobial activity of long-chain alcohols against *Streptococcus mutans*. *J. Agric. Food Chem.* 41:2447-2450.
20. Lewis, R.D., Marken, B.F., Smith, S.R. Anti-plaque efficacy of a chalk-based antimicrobial dentifrice. *SADJ.* 2001 Apr; 56(4): 178-81.

21. Lowry, O.H., Rosenbrough, N.J., Farr, A.L., Randall, R.J. (1951) Protein measurement with the Folin-Phenol reagents. *J. Biol. Chem.* 193:265-275.
22. Ma Y., Rutherford G. C., Curran T. M., Reidmiller J. S., Marquis R. E. Membrane locus pH sensitivity of paraben inhibition of alkali production by oral streptococci. *Oral Microbiology and Immunology*, 14, 244-249. (1999).
23. Nascimento, A.M., de Oliveira, D.C.R. (2001) Kaurene diterpenes and other chemical constituentes from *Mikania stipulata* (M. Vahl) Willd. *J. Braz. Chem. Soc.* 12: 552-555.
24. Ohno, N., Mabry, T.J., Zabel, V., Watson, W.H. (1979) Tetrachyrin, a new rearranged kaurenoic lactone, and diterpene acids from *Tetrachyron orizabaensis* and *Helianthus debilis*. *Phytochemistry* 18: 1687-1689.
25. Osawa, K.; Yasuda, H.; Maruyama, T.; Morita, H.; Takeya, K.; Itokawa, H. (1992) Isoflavanones from the heartwood of *Swartzia polyphylla* and their antibacterial activity against cariogenic bacteria. *Chem. Pharm. Bull.* 40: 2970-4.
26. Pereira, N.A., Pereira, B.M., do Nascimento, M.C., Parente, J.P., Mors, W.B. (1994) Pharmacological screening of plants recommended by folk medicine as snake venom antidotes, IV. Protection against jararaca venom by isolated constituents. *Planta Med*, 60 (2), 99-100.
27. Rios, J.L.; Recio, M.C. and Villar A. (1988)) Screening methods for natural products with antimicrobial activity: a review of the literature. *J. Ethnopharmacol.* 23, 127-149.
28. Ruppelt, B.M., Perreira, E.F., Gonçalves, L.C., Pereira, N.A. (1991) Pharmacological screening of plants recommended by folk medicine as anti-snake venom – I. Analgesic and anti-inflammatory activities. *Mem. Inst. Oswaldo Cruz*, 86, Suppl 2:203-5.
29. SAS Institute Inc (ed) JMP.[®] (1989). *User's Guide: Version 2 of JMP*, Cary, SAS Institute, NJ, USA.
30. Svensäter. G.; Welin, J.; Wilkins, J.C.; Beighton, D.; Hamilton, I.R. (2001) Protein expression by planktonic and biofilm cells on *Streptococcus mutans*. *FEMS Microbiology Letters* 205:139-146.
31. Takahashi, J.A., Vieira, H.S., Boaventura, M.A.D. (2001) Mono and diterpenes from seeds of *Xylopia sericea*. *Quim. Nova* 24: 616-618.

32. Tsutiya, H., Sato, M., Iinuma, M., Yokoyama, J., Ohyama, M., Tanaka, T., Takase, I., Namikawa, I. (1994) Inhibition of the growth of carcinogenic bacteria in vitro by plant flavanones. *Experientia* 50:846-849.
33. Veneziani, R.C.S., Oliveira, D.C.R. (1999) Dictionary of Terpenoids, ed. Connolly J.D., Hill R.A. Chapman and Hall, London, 1993. Constituents of *Mikania glomerata* Sprengel. *Biochemical Systematics and Ecology* 27: 99-102.
34. Yatsuda R, Murata RM, Duarte S, Rosalen PL, Cury JA, Rehder VLG, Koo H. Efeito antimicrobiano da fração hexânica e compostos isolados da *Mikania glomerata* sobre o biofilme dental. In: *Anais da Reunião da Sociedade Brasileira de Pesquisa Odontológica*, 2003. Águas de Lindóia, São Paulo: SBPqO; 2003. p. 225. [Resumo Pc128].
35. Yatsuda, R., Murata, R.M., Duarte, S., Cury, J.A., Rehder, V.G., Koo, H. and Rosalen, P.L. (2002) Effect of *Mikania* genus plant on the growth and cell adherence of mutans streptococci. *Journal of Dental Research*. 81: March (special issue A) A-272, 2117.
36. Yatsuda, R., Murata, R.M., Duarte, S., Rosalen, P.L., Cury, J.A., Rehder, V.G. and Koo, H. (2001) Antimicrobial effect of *Mikania* against *Streptococcus mutans*. *Pesquisa Odontológica Brasileira*. 15: SET (I103) p34.
37. Yatsuda R., Cury, A. P., Rehder, V.G.L., Melo, L. V., Murata, R.M., Duarte, S., Bowen W.H., Marquis, R.E., Rosalen, P.L., Koo, H. (unpublished data) Antimicrobial activity of compounds isolated from *Mikania sp.* on mutans streptococci biofilms.

Figure 1: Structures of compounds isolated from *M. laevigata* and *M. glomerata*






Figure 2. Killing of *S. mutans* UA159 biofilms by the test compounds at 100 times the MIC.




Ent-kaur-16-en-19-oic acid (1) 1000 µg/mL, ent-beyer-15-en-19-oic acid (2) 500 µg/mL, diterpenic acid (3) 250 µg/mL. Vehicle control was used as a negative control. Killing curves were constructed by plotting values in the ordinate label, No stands for the original number of colony – forming units per mL and N stands for the number after the indicated times of exposure. (N=12).

Figure 3. Killing of *S. sobrinus* 6715 biofilms by test compounds at 100 times MIC.




Ent-kaur-16-en-19-oic acid (1) 1000 µg/mL, ent-beyer-15-en-19-oic acid (2) 500 µg/mL, diterpenic acid (3) 250 µg/mL. Vehicle control was used as a negative control. Killing curves were constructed by plotting values in the ordinate label, No stands for the original number of colony – forming units per mL and N stands for the number after the indicated times of exposure. (N=12).

Figure 4. Average number of CFU recovered of the control and after the treatments (120 h old biofilms) per *S. mutans* UA159 biofilms.



Ent-kaur-16-en-19-oic acid (1) 1000 µg/mL, ent-beyer-15-en-19-oic acid (2) 500 µg/mL, diterpenic acid (3) 250 µg/mL. Vehicle control was used as a negative control. Killing curves were constructed by plotting values in the ordinate label, No stands for the original number of colony – forming units per mL and N stands for the number after the indicated times of exposure. (N=12).

Figure 5. Average number of CFU recovered of the control and after the treatments (120 h old biofilms) per *S. sobrinus* 6715 biofilms.



Ent-kaur-16-en-19-oic acid (1) 1000 µg/mL, ent-beyer-15-en-19-oic acid (2) 500 µg/mL, diterpenic acid (3) 250 µg/mL. Vehicle control was used as a negative control. Killing curves were constructed by plotting values in the ordinate label, No stands for the original number of colony – forming units per mL and N stands for the number after the indicated times of exposure. (N=12).

Table 1. Value (means and SD) of dry-weight, total amount of insoluble polysaccharide and protein in the biofilms after treatments.

Treatments	<i>S. mutans</i> UA 159			<i>S. sobrinus</i> 6715		
	Dry-weight	Polysaccharide	Protein	Dry-weight	Polysaccharide	Protein
	mg	µg/mg of biofilm	µg/mg of biofilm	mg	µg/mg of biofilm	µg/mg of biofilm
Vehicle control	37.8±3.1 ^a	375.7±50.1 ^a	274.1±27.4 ^a	22.8±2.6 ^a	353.1±22.5 ^a	325.4±35.5 ^a
Ent-kaur-16-en-19-oic acid (1) 1000 µg/mL	38.8±1.0 ^a	394.2±33.4 ^a	275.4±23.3 ^a	24.1±2.8 ^a	360.4±16.1 ^a	373.9±24.3 ^a
Ent-beyer-15-en-19-oic acid (2) 500 µg/mL	30.1±3.8 ^b	325.5±53.8 ^{ab}	211.3±16.7 ^b	15.1±3.2 ^b	253.9±36.9 ^b	369.7±21.6 ^a
Diterpenic acid (3) 250 µg/mL	31.1±1.3 ^b	302.8±38.9 ^b	207.5±17.9 ^b	14.2±4.1 ^b	241.7±14.4 ^b	235.3±17.7 ^b

Values in the same column followed by the same superscripts are not significantly different from each other ($P>0.05$, ANOVA, comparison for all pairs using Tukey-Kramer HSD test). (N=12).

3. CONCLUSÕES

Este estudo confirma que a fração hexânica e os compostos isolados da *Mikania laevigata* e *Mikania glomerata*, como os ácidos diterpênico e cupressênico apresentam atividades antimicrobianas contra os estreptococos do grupo mutans em células planctônicas e em modelo de biofilme, demonstrando assim que os compostos isolados da *Mikania* são promissores agentes anti-cárie e anti-placa.

4. REFERÊNCIAS BIBLIOGRÁFICAS*

1. Alam S, Brailsford SR, Adams S, Allison C, Sheehy E, Zoitopoulos L, Kidd EA, Beighton D. Genotypic heterogeneity of *Streptococcus oralis* and distinct aciduric subpopulations in human dental plaque. *Appl Environ Microbiol.* 2000 Aug; 66(8): 3330-6.
2. Alves TM, Chaves PP, Santos LM, Nagem TJ, Murta SM, Ceravolo IP, Romanha AJ, Zani CL. A diterpene from *Mikania obtusata* active on *Trypanosoma cruzi*. *Planta Med.* 1995; 61(1): 85-7.
3. Bowden GH. Microbiology of root surface caries in humans. *J Dent Res.* 1990 May; 69(5): 1205-10.
4. Corrêa MP. *Dicionário de plantas úteis do Brasil e das Exóticas cultivadas.* Ministério da Agricultura, Rio de Janeiro. 1942; 3: 517-520.
5. Cruz JPG, Liberalli CHR. *Rev. Flora Med.* 1938; 4(6): 223.
6. Cury JA, Rebello MA, Del Bel Cury AA. In situ relationship between sucrose exposure and the composition of dental plaque. *Caries Res.* 1997; 31(5): 356-60.
7. da Silva, RAD. *Pharmacopéia dos Estados Unidos do Brasil.* São Paulo, Companhia Editora Nacional; 1929.
8. Davino SC, Giesbrecht AM, Roque NF. Antimicrobial activity of kaurenoic acid derivatives substituted on carbon – 15. *Braz. J. Med. Biol. Res.* 1989; 22(9): 1127-9.
9. Dibdin GH, Shellis RP. Analysis of the buffering systems in dental plaque. *J Dent Res.* 1988 Feb; 67(2): 438-46.
10. Egan D, O'Kennedy R, Moran E, Cox D, Prosser E, Thornes RD. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. *Drug Metab Rev.* 1990; 22(5): 503-29.

* De acordo com a norma da FOP/UNICAMP, baseada no modelo Vancouver. Abreviatura dos periódicos em conformidade com o Medline.

11. Elisabetsky E. Pesquisas em plantas medicinais. *Ciência e cultura*. 1997 Ago; 39(8): 697-702.
12. Farnsworth NR. Medicinal plants in therapy. *Bull World Health Organ*. Geneva 1985; 63(3): 965-81.
13. Fierro IM, da Silva AC, Lopes Cda S, de Moura RS, Barja-Fidalgo C. Studies on the anti-allergic activity of *Mikania glomerata*. *J Ethnopharmacol*. 1999 Jul; 66(1): 19-24.
14. Gibbons RJ, Houte JV. Bacterial adherence in oral microbial ecology. *Annu Rev Microbiol*. 1975; 29: 19-44.
15. Gibbs RD. *Chemotaxonomy of flowering plants*. Montreal MC Hill Queens Univ. Press. 1974; 4.
16. Hamada S, Slade HD. Biology, immunology, and cariogenicity of *Streptococcus mutans*. *Microbiol Rev*. 1980 Jun; 44(2): 331-84.
17. Hanada N, Kuramitsu HK. Isolation and characterization of the *Streptococcus mutans* gtfD gene, coding for primer-dependent soluble glucan synthesis. *Infect Immun*. 1989 Jul; 57(7): 2079-85.
18. King RM, Robinson H. The genera of the Eupatorieae (Asteraceae). *Monographs in systematic botany*. Missouri Botanical Garden. 1987; 22.
19. Koo H, Pearson SK, Scott-Anne K, Abranches J, Cury JA, Rosalen PL, Park YK, Marquis RE, Bowen WH. Effects of apigenin and tt-farnesol on glucosyltransferase activity, biofilm viability and caries development in rats. *Oral Microbiol Immunol*. 2002 Dec; 17(6): 337-43.
20. Lewis H, Elvin-Lewis MPF. In: *Medical Botany - Plants Affecting Man's Health*. Nova York: Wiley & Sons; 1977.
21. Loesche WJ. Role of *Streptococcus mutans* in human dental decay. *Microbiol Rev*. 1986 Dec; 50(4): 353-80.
22. Lucas V. *Rev Flora Med*. 1942; 9(3): 101-1.

REFERÊNCIAS BIBLIOGRÁFICAS

23. Marcotte H, Lavoie MC. Oral microbial ecology and the role of salivary immunoglobulin A. *Microbiol Mol Biol Rev.* 1998 Mar; 62(1): 71-109.
24. Marsh PD. Microbiological aspects of the chemical control of plaque and gingivitis. *J Dent Res.* 1992 Jul; 71(7): 1431-8.
25. Marsh PD. Microbial ecology of dental plaque and its significance in health and disease. *Adv Dent Res.* 1994 Jul; 8(2): 263-71.
26. Oliveira F. *et al.* Isolation and identification of chemical components of *Mikania glomerata* Sprengel and *Mikania laevigata* Schultz Bib ex Baker. *Rev. Fac. Farm. Bioquim. Univ. São Paulo.* 1984; 20(2): 169-83.
27. Pereira NA, Pereira BM, do Nascimento MC, Parente JP, Mors WB. Pharmacological screening of plants recommended by folk medicine as snake venom antidotes; IV. Protection against jararaca venom by isolated constituents. *Planta Med.* 1994 Apr; 60(2): 99-100.
28. Ritter MR, Baptista LRM, Matzenbacher NI. Boletim do Instituto de Ciências. 1992; 50: 11.
29. Rölla G, Ciardi JE, Eggen K. Free glucosyl and fructosyltransferase in human saliva and adsorption of these enzymes to teeth *in vivo*. In: Doyle RJ, Ciardi JE editors. *Glucosyltransferases, glucans, sucrose and dental caries*. Washington, IRL Press, 1983; 21-30. [Chemical Senses, Sp. Suppl.].
30. Roskopf F, Kraus J, Franz G. Immunological and antitumor effects of coumarin and some derivatives. *Pharmazie.* 1992 Feb; 47(2): 139-42.
31. Ruppelt BM, Pereira EF, Goncalves LC, Pereira NA. Pharmacological screening of plants recommended by folk medicine as anti-snake venom--I. Analgesic and anti-inflammatory activities. *Mem Inst Oswaldo Cruz.* 1991; 86 Suppl 2: 203-5.
32. Santos TC, Cosca S, Tonassini T. *Mikania glomerata* Sprengel- Estudo químico de seus componentes. In: *Congresso brasileiro de plantas medicinais*, Curitiba, Universidade Federal do Paraná, 1992; p. 149.

REFERÊNCIAS BIBLIOGRÁFICAS

33. Schilling KM, Bowen WH. Glucans synthesized in situ in experimental salivary pellicle function as specific binding sites for *Streptococcus mutans*. *Infect Immun*. 1992 Jan; 60(1): 284-95.
34. Tanzer, JM, Freedman ML, Fitzgerald RJ. *et al* Virulence of mutans defective in glucosyltransferase, dextran-mediated aggregation, or dextranase activity. In: Mergenhagen SE, Rosan B, editors. *Molecular basis of oral microbial adhesion*. American society for microbiology. Washington, DC, USA.
35. Ten Cate JM, Marsh PD. Procedures for establishing efficacy of antimicrobial agents for chemotherapeutic caries prevention. *J Dent Res*. 1994 Mar; 73(3): 695-703.
36. van Houte J. Role of micro-organisms in caries etiology. *J Dent Res*. 1994 Mar; 73(3): 672-81.
37. Yatsuda R, Murata RM, Duarte S, Rosalen PL, Cury JA, Rehder VLG, Koo H. Efeito antimicrobiano da *Mikania* sobre os *Streptococcus mutans*. In: *Anais da Reunião da Sociedade Brasileira de Pesquisa Odontológica*, 2001. Águas de Lindóia, São Paulo: SBPqO; 2001. p. 34. [Resumo I103].
38. Yatsuda R, Murata RM, Duarte S, Rosalen PL, Cury JA, Rehder VLG, Koo H. Effect of *Mikania* genus plant on the growth and cell adherence of mutans streptococci. In: *J Dent Res*, 2002. Special Issue A (San Diego Abstracts) IADR; 2002. p. A-272. [Abstract 2117].
39. Yatsuda R, Murata RM, Duarte S, Rosalen PL, Cury JA, Rehder VLG, Koo H. Efeito antimicrobiano da fração hexânica e compostos isolados da *Mikania glomerata* sobre o biofilme dental. In: *Anais da Reunião da Sociedade Brasileira de Pesquisa Odontológica*, 2003. Águas de Lindóia, São Paulo: SBPqO; 2003. p. 225. [Resumo Pc128].

5. ANEXOS

5.1. ANEXO 01. E-mail de recebimento do artigo pela revista Journal of Ethnopharmacology.

YAHOO! Mail  [Yahoo!](#) - [Meu Yahoo!](#) - [Ajuda](#)

 [E-mail](#)  [Endereços](#)  [Agenda](#)  [Bloco de notas](#) **reyatsuda@yahoo.com** [\[Sair\]](#)

[Checar e-mail](#) [Escrever](#) [Buscar mensagem](#) - [Opções do Yahoo! Mail](#)

Ver outro e-mail [\[Editar\]](#)

[hotmail.com](#)

[www.hotmail.com](#)

Pastas [\[Adicionar\]](#)

 [Entrada \(1\)](#)

 [Rascunho](#)

 [Enviadas](#)

 [Em massa \(7\)](#) [\[Limpar\]](#)

 [Lixeira](#) [\[Limpar\]](#)

Minhas pastas [\[Ocultar\]](#)

 [Cartões](#)

 [Firmas](#)

 [Formatura](#)

 [Pesquisa](#)

 [histórias](#)

[Anterior](#) | [Próxima](#) | [Voltar](#) [Imprimir](#) - [Cabeçalhos](#)

[Apagar](#) [em anexo](#)

Mensagem não sinalizada. [[Sinalizar](#) - [Marcar como não lida](#)]

Caro Cliente

Em atenção à sua solicitação, informamos que o objeto EE029906975BR foi entregue ao destinatário em 12/02/2004. Quanto ao aviso de recebimento, esclarecemos que o mesmo retorna na modalidade simples, com um prazo maior para devolução ao remetente.

Atenciosamente,

Central de Atendimento aos Clientes dos Correios

Sua pergunta foi:

Pedido de informação sobre objeto postado.
 Tipo objeto: Surpostal Expresso
 Motivo Solicitação: Remetente não recebeu o ARNome
 Destinatário: Dr R. Verpoorte -Journal of Ethnopharmacology
 Endereço destinatário: Leiden University- P.O. Box 950/2300 RA Leiden
 Cidade destinatário: RA LeidenUF
 destinatário: XXPaís destinatário:
 HOLANDACEP destinatário: P.O. BoxNúmero registro: EE029906975BRPeso (gramas):

Preço Postal: 49,80
Embalagem: envelope Agência Postagem:
74302744
Local postagem: PIRACICABA-AV. ARMANDO
SALES
Data postagem: 07/02/2004
Valor Declarado: Aviso recebimento: Sim
Observações: CPF/CNPJ do Remetente:
28877351870 Banco: () Agência: Conta:

Apagar

em anexo

[Anterior](#) | [Próxima](#) | [Voltar](#)
[às mensagens](#)

[Salvar texto da
mensagem](#)

[Checar e-mail](#) [Escrever](#)

[Buscar mensagem](#) - [Opções do Yahoo! Mail](#)

[E-mail](#) - [Endereços](#) - [Agenda](#) - [Bloco de notas](#)

Copyright © 1994-2004 [Yahoo! do Brasil Internet Ltda.](#) Todos os direitos reservados. [Termos do Serviço](#)

AVISO: Nós coletamos informações pessoais neste site.

Para saber mais sobre como nós usamos suas informações, consulte nossa [Política de Privacidade](#)